Compositions and methods for biological production of fatty acid derivatives

ABSTRACT

The present disclosure provides compositions and methods for biologically producing fatty acid derivatives, such as fatty alcohols, from recombinant C1 metabolizing microorganisms that utilize C1 substrates such as methane or natural gas as a feedstock.

BACKGROUND Technical Field

The present disclosure provides compositions and methods forbiologically producing fatty acid derivatives and, more specifically,using recombinant C₁ metabolizing microorganisms to produce fattyalcohols, hydroxy fatty acids, or dicarboxylic acids from C₁ substrates(such as methane or natural gas).

Background Description

Fatty alcohols are aliphatic alcohols that are predominantly linear andmonohydric. They are composed of a nonpolar lipophilic, saturated orunsaturated hydrocarbon chain, usually from C₆ to C₂₄, and a polar,hydrophilic hydroxyl group attached to the terminal carbon. Fattyalcohols are high value chemicals with a multitude of applications, suchas surfactants, detergents, lubricant additives, defoamers, solubilityretarders, and consistency giving factors. Fatty alcohol productioncapacity was approximately 2 million metric tons per year in 2009.Included in the capacity are C₁₂/C₁₄ alcohols, C₁₆/C₁₈ alcohols, andC₁₅/C₁₈ alcohols. The global surfactant market is expected to reach$16.65 billion by 2012. Nonionic surfactants constitute the secondlargest group of products in the surfactant market. Fatty acid basedsurfactants represent some 20% of the nonionic type of surfactants.

Currently the fatty alcohol market is dominated by natural alcohol andsynthetic alcohol products. Natural alcohols are prepared from naturaloils, fats, and waxes of plants or animals, such as coconut or palm oil,using transesterification and hydrogenation processes. Syntheticalcohols are produced from petrochemical feedstocks such as ethene,olefins and paraffins, mainly from the Ziegler alcohol process, SHOPprocess, and Oxo process. However, these processes either require harshproduction environments, questionable land use practices, orenvironmentally detrimental byproducts.

Increasing efforts have been made to enable microbial production offatty alcohols from abundant and cost-effective renewable resources. Inparticular, recombinant microorganisms, such as E. coli and variousyeasts, have been used to convert biomass-derived feedstocks to fattyalcohols, such as lauryl alcohol. However, even with the use ofrelatively inexpensive cellulosic biomass as a feedstock, more than halfthe mass of carbohydrate feedstocks is comprised of oxygen, whichrepresents a significant limitation in conversion efficiency. Long chainfatty acids and their derivatives (such as fatty alcohols, hydroxy-fattyacids, fatty aldehydes) have significantly lower oxygen content than thefeedstocks, which limits the theoretical yield as the oxygen must beeliminated as waste. Thus, the economics of production of fatty acidsand their derivatives from carbohydrate feedstocks is prohibitivelyexpensive.

In view of the limitations associated with carbohydrate-basedfermentation methods for production of fatty alcohol and relatedcompounds, there is a need in the art for alternative, cost-effective,and environmentally friendly methods for producing fatty alcohols. Thepresent disclosure meets such needs, and further provides other relatedadvantages.

BRIEF SUMMARY

In certain aspects, the present disclosure is directed to a method formaking a fatty acid derivative by culturing a non-natural C₁metabolizing non-photosynthetic microorganism with a C₁ substratefeedstock and recovering the fatty acid derivative, wherein the C₁metabolizing non-photosynthetic microorganism comprises a recombinantnucleic acid molecule encoding a fatty acid converting enzyme, andwherein the C₁ metabolizing non-photosynthetic microorganism convertsthe C₁ substrate into a C₈-C₂₄ fatty acid derivative comprising a fattyaldehyde, a fatty alcohol, a hydroxy fatty acid, a dicarboxylic acid, ora combination thereof.

In a related aspect, the present disclosure provides a non-naturalmethanotroph, comprising a recombinant nucleic acid molecule encoding afatty acid converting enzyme, wherein the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ fatty aldehyde, fatty alcohol,fatty ester wax, a hydroxy fatty acid, dicarboxylic acid, or acombination thereof. In certain embodiments, there are providednon-natural methanotrophs containing a recombinant nucleic acid moleculeencoding a heterologous acyl-CoA dependent or independent fatty acyl-CoAreductase, a recombinant nucleic acid molecule encoding a heterologousthioesterase, and a recombinant nucleic acid molecule encoding aheterologous acyl-CoA synthetase, wherein the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ fatty alcohol.

In further embodiments, there are provided non-natural methanotrophscontaining a recombinant nucleic acid molecule encoding a carboxylicacid reductase, a recombinant nucleic acid molecule encoding aphosphopantetheinyl tranferase, and a recombinant nucleic acid moleculeencoding an alcohol dehydrogenase, wherein the methanotroph is capableof converting a C₁ substrate into a C₈-C₂₄ fatty alcohol.

In still further embodiments, provided are non-natural methanotrophscontaining a recombinant nucleic acid molecule encoding a heterologousfatty acyl-CoA reductase, a recombinant nucleic acid molecule encoding aheterologous thioesterase, and a recombinant nucleic acid moleculeencoding a heterologous P450 or monooxygenase, wherein the nativealcohol dehydrogenase is inhibited and the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ ω-hydroxy fatty acid.

In yet further embodiments, there are provided non-natural methanotrophscontaining a recombinant nucleic acid molecule encoding a heterologousfatty acyl-CoA reductase, and a recombinant nucleic acid moleculeencoding a heterologous thioesterase, wherein the methanotroph isover-expressing native alcohol dehydrogenase as compared to the normalexpression level of native alcohol dehydrogenase, transformed with arecombinant nucleic acid molecule encoding a heterologous alcoholdehydrogenase, or both, and wherein the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ dicarboxylic acid alcohol.

In another aspect, the present disclosure provides a C₁ metabolizingmicroorganism biomass comprising a fatty acid derivative composition,wherein the fatty acid derivative containing biomass or a fatty acidderivative composition therefrom has a δ¹³C of about −35‰ to about −50‰,−45‰ to about −35‰, or about −50‰ to about −40‰, or about −45‰ to about−65‰, or about −60‰ to about −70‰, or about −30‰ to about −70‰. Incertain embodiments, a fatty acid derivative composition comprises fattyaldehyde, fatty alcohol, fatty ester wax, hydroxy fatty acid,dicarboxylic acid, or any combination thereof. In still furtherembodiments, a fatty acid derivative composition comprises C₈-C₂₄ fattyalcohol, C₈-C₂₄ branched chain fatty alcohol, C₈-C₂₄ fatty aldehyde,C₈-C₂₄ w-hydroxy fatty acid, or C₈-C₂₄ dicarboxylic acid alcohol. In yetfurther embodiments, a fatty acid derivative composition comprises amajority (more than 50% w/w) of fatty acids having carbon chain lengthsranging from C₈ to C₁₄ or from C₁₀ to C₁₆ or from C₁₄ to C₂₄, or amajority of fatty acid derivatives having carbon chain lengths of lessthan C₁₈, or a fatty alcohol containing composition wherein at least 70%of the total fatty alcohol comprises C₁₀ to C₁₈ fatty alcohol.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows an overview of an acyl-CoA dependent FAR Pathway for fattyalcohol production.

FIG. 2 shows an overview of an acyl-CoA independent FAR pathway forfatty alcohol production.

FIG. 3 shows an overview of an acyl-CoA independent CAR pathway forfatty alcohol production.

FIG. 4 shows an overview of a w-hydroxy fatty acid production pathway.

FIG. 5 shows an overview of a dicarboxylic acid production pathway.

FIG. 6 shows an overview of an acyl-CoA dependent FAR pathway for fattyester production.

FIG. 7 shows a schematic of the δ¹³C distribution of various carbonsources.

DETAILED DESCRIPTION

The instant disclosure provides compositions and methods for generatingfatty acid derivatives. For example, recombinant C₁ metabolizingmicroorganisms are cultured with a C₁ substrate feedstock (e.g.,methane) to generate C₈ to C₂₄ fatty aldehyde, fatty alcohol, fattyester wax, hydroxy fatty acid, dicarboxylic acid, or any combinationthereof. This new approach allows for the use of methylotroph ormethanotroph bacteria as a new host system to generate fatty acidderivatives for use in producing, for example, surfactants, lubricants,solvents, or detergents.

By way of background, methane from a variety of sources, includingnatural gas, represents an abundant domestic resource. As noted above,carbohydrate based feedstocks contain more than half of their mass inoxygen, which is a significant limitation in conversion efficiency aslong chain fatty alcohols have significantly lower oxygen content thanthese feedstocks. A solution to address the limitations of currentsystems is to utilize methane or natural gas as a feedstock forconversion. Methane from natural gas is cheap and abundant, andimportantly contains no oxygen, which allows for significantimprovements in theoretical conversion efficiency. Furthermore, C₁carbon sources are cheap and abundant compared to carbohydratefeedstocks, which also contributes to improved economics of fattyalcohol production.

Fatty acid production is an important pathway in virtually all organismsas it is required for membrane biosynthesis. In the present disclosure,metabolic engineering techniques are applied to increase overall carbonflux to the production of fatty acids, for example, by over-expressinggenes associated with fatty acid biosynthesis (e.g., acyl-coA synthase,acetyl-coA carboxylase, acyl carrier protein, pyruvate dehydrogenase)while simultaneously inhibiting, down-regulating or eliminating enzymesassociated with fatty acid degradation or competing metabolic pathways.In additional embodiments, the composition and chain length of fattyacids are controlled by introducing heterologous thioesterase genes thatare specific for a desired chain length while optionally inhibiting,down-regulating or eliminating native thioesterase genes (e.g., inbacteria, introducing fatB1 thioesterase from Umbellularia californica,which selectively produces C₁₂ fatty acid chains, and eliminating thenative thioesterases that typically produce chain lengths of C₁₆-C₁₈ inbacteria). In still further embodiments, branched chain fatty acids areproduced by introduction of various enzymes in the branched chainα-ketoacid synthesis pathway (branched chains also provide significantadvantages for some surfactant and detergent applications).

In one aspect, the present disclosure provides a method for a fatty acidderivative, comprising culturing a non-natural C₁ metabolizingnon-photosynthetic microorganism in the presence of a C₁ substratefeedstock and recovering the fatty acid derivative, wherein the C₁metabolizing non-photosynthetic microorganism comprises a recombinantnucleic acid molecule encoding a fatty acid converting enzyme, andwherein the C₁ metabolizing non-photosynthetic microorganism convertsthe C₁ substrate into a C₈-C₂₄ fatty acid derivative comprising a fattyaldehyde, a fatty alcohol, a fatty ester wax, a hydroxy fatty acid, adicarboxylic acid, or a combination thereof. In another aspect, thisdisclosure provides a non-natural methanotroph that includes arecombinant nucleic acid molecule encoding a fatty acid convertingenzyme, wherein the methanotroph is capable of converting a C₁ substrateinto a C₈-C₂₄ fatty aldehyde, fatty alcohol, fatty ester wax, hydroxyfatty acid, dicarboxylic acid, or a combination thereof.

Prior to setting forth this disclosure in more detail, it may be helpfulto an understanding thereof to provide definitions of certain terms tobe used herein. Additional definitions are set forth throughout thisdisclosure.

In the present description, any concentration range, percentage range,ratio range, or integer range is to be understood to include the valueof any integer within the recited range and, when appropriate, fractionsthereof (such as one tenth and one hundredth of an integer), unlessotherwise indicated. Also, any number range recited herein relating toany physical feature, such as polymer subunits, size or thickness, areto be understood to include any integer within the recited range, unlessotherwise indicated. As used herein, the term “about” means±20% of theindicated range, value, or structure, unless otherwise indicated. Theterm “consisting essentially of” limits the scope of a claim to thespecified materials or steps, or to those that do not materially affectthe basic and novel characteristics of the claimed invention. It shouldbe understood that the terms “a” and “an” as used herein refer to “oneor more” of the enumerated components. The use of the alternative (e.g.,“or”) should be understood to mean either one, both, or any combinationthereof of the alternatives. As used herein, the terms “include,” “have”and “comprise” are used synonymously, which terms and variants thereofare intended to be construed as non-limiting.

As used herein, the term “recombinant” or “non-natural” refers to anorganism, microorganism, cell, nucleic acid molecule, or vector thatincludes at least one genetic alternation or has been modified by theintroduction of an exogenous nucleic acid, or refers to a cell that hasbeen altered such that the expression of an endogenous nucleic acidmolecule or gene can be controlled, where such alterations ormodifications are introduced by genetic engineering. Genetic alterationsinclude, for example, modifications introducing expressible nucleic acidmolecules encoding proteins or enzymes, other nucleic acid additions,nucleic acid deletions, nucleic acid substitutions, or other functionaldisruption of the cell's genetic material. Such modifications include,for example, coding regions and functional fragments thereof forheterologous or homologous polypeptides for the referenced species.Additional modifications include, for example, non-coding regulatoryregions in which the modifications alter expression of a gene or operon.Exemplary proteins or enzymes include proteins or enzymes (i.e.,components) within a fatty acid biosynthesis pathway (e.g., fattyacyl-CoA reductase, a thioesterase, acyl-CoA synthetase, or acombination thereof). Genetic modifications to nucleic acid moleculesencoding enzymes, or functional fragments thereof, can confer abiochemical reaction capability or a metabolic pathway capability to therecombinant cell that is altered from its naturally occurring state.

The following abbreviations of enzyme names are used herein: “fatty acylreductase” or “fatty alcohol forming acyl-CoA reductase” is referred toas “FAR”; “acyl carrier protein” is referred to as “ACP”; “coenzyme A”is referred to as “CoA”; “thioesterase” is referred to as “TE”; “fattyacid synthase” or “fatty acid synthetase” is referred to as “FAS”;“fatty acyl-CoA reductase” is referred to as “FACR”; “fatty acyl-CoAsynthase” or “fatty acyl-CoA synthetase” or “acyl-CoA synthase” or“acyl-CoA synthetase” are used interchangeably herein and are referredto as “FACS”; and “acetyl-CoA carboxylase” is referred to as “ACC”.

Fatty Acyl Reductase (FAR), as shown in FIG. 1 and used herein, refersto an enzyme that catalyzes the reduction of a fatty acyl-CoA, a fattyacyl-ACP, or other fatty acyl thioester complex (each having a structureof R—(CO)—S—R₁, Formula I) to a fatty alcohol (structure R—OH, FormulaII). For example, R—(CO)—S—R₁ (Formula I) is converted to R—OH (FormulaII) and R₁—SH (Formula III) when two molecules of NADPH are oxidized toNADP⁺, wherein R is a C₈ to C₂₄ saturated, unsaturated, linear, branchedor cyclic hydrocarbon, and R₁ represents CoA, ACP or other fatty acylthioester substrate. CoA is a non-protein acyl carrier group involved inthe synthesis and oxidation of fatty acids. “ACP” is a polypeptide orprotein subunit of FAS used in the synthesis of fatty acids. FARs aredistinct from FACRs. FACRs reduce only fatty acyl-CoA intermediates tofatty aldehydes and require an additional oxidoreductase enzyme togenerate the corresponding fatty alcohol. Fatty aldehyde, as used herein(see FIG. 1), refers to a saturated or unsaturated aliphatic aldehyde,wherein R is as defined above.

The term “fatty acid” as used herein refers to a compound of structureR—COOH (Formula IV), wherein R is a C₈ to C₂₄ saturated, unsaturated,linear, branched or cyclic hydrocarbon and the carboxyl group is atposition 1. Saturated or unsaturated fatty acids can be described as“Cx:y”, wherein “x” is an integer that represents the total number ofcarbon atoms and “y” is an integer that refers to the number of doublebonds in the carbon chain. For example, a fatty acid referred to asC12:0 or 1-dodecanoic acid means the compound has 12 carbons and zerodouble bonds.

The term “hydroxyl fatty acid” as used herein refers to a compound ofstructure OH—R—COOH (Formula V), wherein R is a C₈ to C₂₄ saturated,unsaturated, linear, branched or cyclic hydrocarbon. Omega hydroxy fattyacids (also known as ω-hydroxy acids) are a class of naturally occurringstraight-chain aliphatic organic acids having a certain number of carbonatoms long with the carboxyl group at position 1 and a hydroxyl atposition n. For example, exemplary C₁₆ ω-hydroxy fatty acids are16-hydroxy palmitic acid (having 16 carbon atoms, with the carboxylgroup at position 1 and the hydroxyl group at position 16) and10,16-dihydroxy palmitic acid (having 16 carbon atoms, with the carboxylgroup at position 1, a first hydroxyl group at position 10, and a secondhydroxyl group at position 16).

The term “fatty alcohol” as used herein refers to an aliphatic alcoholof Formula II, wherein R is a C₈ to C₂₄ saturated, unsaturated, linear,branched or cyclic hydrocarbon. Saturated or unsaturated fatty alcoholscan be described as “Cx:y-OH”, wherein “x” is an integer that representsthe total number of carbon atoms in the fatty alcohol and “y” is aninteger that refers to the number of double bonds in carbon chain.

Unsaturated fatty acids or fatty alcohols can be referred to as“cisΔ^(z)” or “transΔ^(z)”, wherein “cis” and “trans” refer to thecarbon chain configuration around the double bond and “z” indicates thenumber of the first carbon of the double bond, wherein the numberingbegins with the carbon having the carboxylic acid of the fatty acid orthe carbon bound to the —OH group of the fatty alcohol.

The term “fatty acyl-thioester” or “fatty acyl-thioester complex” refersto a compound of Formula I, wherein a fatty acyl moiety is covalentlylinked via a thioester linkage to a carrier moiety. Fattyacyl-thioesters are substrates for the FAR enzymes described herein.

The term “fatty acyl-CoA” refers to a compound of Formula I, wherein R₁is Coenzyme A, and the term “fatty acyl-ACP” refers to a compound ofFormula I, wherein R₁ is an acyl carrier protein ACP).

The phrase “acyl-CoA independent pathway” refers to the production offatty alcohols by the direct enzymatic conversion of fatty acyl-ACPsubstrates to fatty alcohols and does not involve the use of free fattyacids or fatty acyl-CoA intermediates. This biosynthetic pathway differsfrom two types of fatty acyl-CoA dependent pathways—one that convertsfatty acyl-ACP directly to fatty acyl CoA via an acyl-transfer reaction,and a second that converts fatty acyl-ACP to fatty acyl-CoA via a freefatty acid intermediate (see FIG. 1). The acyl-CoA independent pathwayhas the advantage of bypassing the step of form a fatty acyl-CoAsubstrate from free fatty acid, which requires the use of ATP.Therefore, the acyl-CoA independent pathway may use less energy than theacyl-CoA dependent pathway that utilizes a free fatty acid intermediate.

As used herein, “alcohol dehydrogenase” (ADH) refers to any enzymecapable of converting an alcohol into its corresponding aldehyde,ketone, or acid. An alcohol dehydrogenase may have general specificity,capable of converting at least several alcohol substrates, or may havenarrow specificity, accepting one, two or a few alcohol substrates. Asused herein, “particulate methane monooxygenase” (pMMO) refers to amembrane-bound particulate enzyme that catalyzes the oxidation ofmethane to methanol in methanotrophic bacteria. The term pMMO meanseither the multi-component enzyme or the subunit comprising the enzyme'sactive site.

As used herein, “soluble methane monooxygenase” (sMMO) refers to anenzyme found in the soluble fraction of cell lysates (cytoplasm) thatcatalyzes the oxidation of methane to methanol in methanotrophicbacteria. The term sMMO means either the multi-component enzyme or thesubunit comprising the enzyme's active site.

As used herein, “P450,” also known as “cytochrome P450” or “CYP,” refersto a group of enzymes with broad substrate specificity that catalyze theoxidation of organic compounds, including lipids, steroidal hormones,and xenobiotic substances. The P450 enzyme most commonly catalyzes amonooxgenase reaction by inserting an oxygen atom into the R—H bond ofan organic substrate.

“Conversion” refers to the enzymatic conversion of a substrate to one ormore corresponding products. “Percent conversion” refers to the percentof substrate that is reduced to one or more products within a period oftime under specified conditions. Thus, the “enzymatic activity” or“activity” of a polypeptide enzyme can be expressed as “percentconversion” of a substrate to product.

As used herein, the term “host” refers to a microorganism (e.g.,methanotroph) that is being genetically modified with fatty acidbiosynthesis components (e.g., thioesterase, fatty acyl-CoA reductase)to convert a C₁ substrate feedstock into a C₈-C₂₄ fatty aldehyde, fattyalcohol, fatty ester wax, a hydroxy fatty acid, dicarboxylic acid, orany combination thereof. A host cell may already possess other geneticmodifications that confer desired properties unrelated to the fatty acidbiosynthesis pathway disclosed herein. For example, a host cell maypossess genetic modifications conferring high growth, tolerance ofcontaminants or particular culture conditions, ability to metabolizeadditional carbon substrates, or ability to synthesize desirableproducts or intermediates.

As used herein, the term “methanotroph,” “methanotrophic bacterium” or“methanotrophic bacteria” refers to a methylotrophic bacteria capable ofutilizing C₁ substrates, such as methane or unconventional natural gas,as its primary or sole carbon and energy source. As used herein,“methanotrophic bacteria” include “obligate methanotrophic bacteria”that can only utilize C₁ substrates for carbon and energy sources and“facultative methanotrophic bacteria” that are naturally able to usemulti-carbon substrates, such as acetate, pyruvate, succinate, malate,or ethanol, in addition to C₁ substrates as their sole carbon and energysource. Facultative methanotrophs include some species of Methylocella,Methylocystis, and Methylocapsa (e.g., Methylocella silvestris,Methylocella palustris, Methylocella tundrae, Methylocystis daltona SB2,Methylocystis bryophila, and Methylocapsa aurea KYG), andMethylobacterium organophilum (ATCC 27,886).

As used herein, the term “C₁ substrate” or “C₁ compound” refers to anorganic compound having lacking carbon to carbon bonds. C₁ substratesinclude syngas, natural gas, unconventional natural gas, methane,methanol, formaldehyde, formic acid (formate), carbon monoxide, carbondioxide, methylated amines (e.g., methylamine, dimethylamine,trimethylamine, etc.), methylated thiols, methyl halogens (e.g.,bromomethane, chloromethane, iodomethane, dichloromethane, etc.), andcyanide.

As used herein, “C₁ metabolizing microorganism” or “C₁ metabolizingnon-photosynthetic microorganism” refers to any microorganism having theability to use a C₁ substrate as a source of energy or as its primarysource of energy or as its sole source of energy and biomass, and may ormay not use other carbon substrates (such as sugars and complexcarbohydrates) for energy and biomass. For example, a C₁ metabolizingmicroorganism may oxidize a C₁ substrate, such as methane, natural gas,or methanol. C₁ metabolizing microorganisms include bacteria (such asMethanotrophs and Methylotrophs) and yeast. In certain embodiments, a C₁metabolizing microorganism does not include a photosyntheticmicroorganism, such as algae. In certain embodiments, a C₁ metabolizingmicroorganism will be an “obligate C₁ metabolizing microorganism,”meaning its primary source of energy are C₁ substrates. In furtherembodiments, a C₁ metabolizing microorganism (e.g., methanotroph) willbe cultured in the presence of a C₁ substrate feedstock (i.e., using theC₁ substrate as the primary or sole source of energy).

As used herein, the term “methylotroph” or “methylotrophic bacteria”refers to any bacteria capable of oxidizing organic compounds that donot contain carbon-carbon bonds. In certain embodiments, amethylotrophic bacterium may be a methanotroph. For example,“methanotrophic bacteria” refers to any methylotrophic bacteria thathave the ability to oxidize methane as it primary source of carbon andenergy. Exemplary methanotrophic bacteria include Methylomonas,Methylobacter, Methylococcus, Methylosinus, Methylocystis,Methylomicrobium, or Methanomonas. In certain other embodiments, themethylotrophic bacterium is an “obligate methylotrophic bacterium,”which refers to bacteria that are limited to the use of C₁ substratesfor the generation of energy.

As used herein, the term “CO utilizing bacterium” refers to a bacteriumthat naturally possesses the ability to oxidize carbon monoxide (CO) asa source of carbon and energy. Carbon monoxide may be utilized from“synthesis gas” or “syngas”, a mixture of carbon monoxide and hydrogenproduced by gasification of any organic feedstock, such as coal, coaloil, natural gas, biomass, and waste organic matter. CO utilizingbacterium does not include bacteria that must be genetically modifiedfor growth on CO as its carbon source.

As used herein, “natural gas” refers to naturally occurring gas mixturesthat have formed in porous reservoirs and can be accessed byconventional processes (e.g., drilling) and are primarily made up ofmethane, but may also have other components such as carbon dioxide,nitrogen or hydrogen sulfide.

As used herein, “unconventional natural gas” refers to a naturallyoccurring gas mixture created in formations with low permeability thatmust be accessed by unconventional methods, such as hydraulicfracturing, horizontal drilling or directional drilling. Exemplaryunconventional natural gas deposits include tight gas sands formed insandstone or carbonate, coal bed methane formed in coal deposits andadsorbed in coal particles, shale gas formed in fine-grained shale rockand adsorbed in clay particles or held within small pores ormicrofractures, methane hydrates that are a crystalline combination ofnatural gas and water formed at low temperature and high pressure inplaces such as under the oceans and permafrost.

As used herein, “syngas” refers to a mixture of carbon monoxide (CO) andhydrogen (H₂). Syngas may also include CO₂, methane, and other gases insmaller quantities relative to CO and H₂.

As used herein, “methane” refers to the simplest alkane compound withthe chemical formula CH₄. Methane is a colorless and odorless gas atroom temperature and pressure. Sources of methane include naturalsources, such as natural gas fields, “unconventional natural gas”sources (such as shale gas or coal bed methane, wherein content willvary depending on the source), and biological sources where it issynthesized by, for example, methanogenic microorganisms, and industrialor laboratory synthesis. Methane includes pure methane, substantiallypurified compositions, such as “pipeline quality natural gas” or “drynatural gas”, which is 95-98% percent methane, and unpurifiedcompositions, such as “wet natural gas”, wherein other hydrocarbons havenot yet been removed and methane comprises more than 60% of thecomposition.

As used herein, “nucleic acid molecule,” also known as a polynucleotide,refers to a polymeric compound comprised of covalently linked subunitscalled nucleotides. Nucleic acid molecules include polyribonucleic acid(RNA), polydeoxyribonucleic acid (DNA), both of which may be single ordouble stranded. DNA includes cDNA, genomic DNA, synthetic DNA,semi-synthetic DNA, or the like.

As used herein, “transformation” refers to the transfer of a nucleicacid molecule (e.g., exogenous or heterologous nucleic acid molecule)into a host. The transformed host may carry the exogenous orheterologous nucleic acid molecule extra-chromosomally or the nucleicacid molecule may integrate into the chromosome. Integration into a hostgenome and self-replicating vectors generally result in geneticallystable inheritance of the transformed nucleic acid molecule. Host cellscontaining the transformed nucleic acids are referred to as“recombinant” or “non-naturally occurring” or “genetically engineered”or “transformed” or “transgenic” cells (e.g., bacteria).

As used herein, the term “endogenous” or “native” refers to a gene,protein, compound or activity that is normally present in a host cell.

As used herein, “heterologous” nucleic acid molecule, construct orsequence refers to a nucleic acid molecule or portion of a nucleic acidmolecule sequence that is not native to a host cell or is a nucleic acidmolecule with an altered expression as compared to the native expressionlevels in similar conditions. For example, a heterologous controlsequence (e.g., promoter, enhancer) may be used to regulate expressionof a native gene or nucleic acid molecule in a way that is differentfrom the way a native gene or nucleic acid molecule is normallyexpressed in nature or culture. In certain embodiments, heterologousnucleic acid molecules may not be endogenous to a host cell or hostgenome, but instead may have been added to a host cell by conjugation,transformation, transfection, electroporation, or the like, wherein theadded molecule may integrate into the host genome or can exist asextra-chromosomal genetic material (e.g., as a plasmid or other selfreplicating vector). In addition, “heterologous” can refer to an enzyme,protein or other activity that is different or altered from that foundin a host cell, or is not native to a host cell but instead is encodedby a nucleic acid molecule introduced into the host cell. The term“homologous” or “homolog” refers to a molecule or activity found in orderived from a host cell, species or strain. For example, a heterologousnucleic acid molecule may be homologous to a native host cell gene, butmay have an altered expression level or have a different sequence orboth.

In certain embodiments, more than one heterologous nucleic acidmolecules can be introduced into a host cell as separate nucleic acidmolecules, as a polycistronic nucleic acid molecule, as a single nucleicacid molecule encoding a fusion protein, or any combination thereof, andstill be considered as more than one heterologous nucleic acid. Forexample, as disclosed herein, a C₁ metabolizing microorganism can bemodified to express two or more heterologous or exogenous nucleic acidmolecules encoding desired fatty acid biosynthesis pathway components(e.g., thioesterase, fatty acyl-CoA reductase, alcohol dehydrogenase).When two or more exogenous nucleic acid molecules encoding fatty acidbiosynthesis pathway components are introduced into a host C₁metabolizing microorganism, it is understood that the two more exogenousnucleic acid molecules can be introduced as a single nucleic acidmolecule, for example, on a single vector, on separate vectors, can beintegrated into the host chromosome at a single site or multiple sites,and still be considered two or more exogenous nucleic acid molecules.Thus, the number of referenced heterologous nucleic acid molecules orprotein activities refers to the number of encoding nucleic acidmolecules or the number of protein activities, not the number ofseparate nucleic acid molecules introduced into a host cell.

The term “chimeric” refers to any nucleic acid molecule or protein thatis not endogenous and comprises sequences joined or linked together thatare not normally found joined or linked together in nature. For example,a chimeric nucleic acid molecule may comprise regulatory sequences andcoding sequences that are derived from different sources, or regulatorysequences and coding sequences that are derived from the same source butarranged in a manner different than that found in nature.

The “percent identity” between two or more nucleic acid sequences is afunction of the number of identical positions shared by the sequences(i.e., % identity=number of identical positions/total number ofpositions×100), taking into account the number of gaps, and the lengthof each gap that needs to be introduced to optimize alignment of two ormore sequences. The comparison of sequences and determination of percentidentity between two or more sequences can be accomplished using amathematical algorithm, such as BLAST and Gapped BLAST programs at theirdefault parameters (e.g., Altschul et al., J. Mol. Biol. 215:403, 1990;see also BLASTN at www.ncbi.nlm.nih.gov/BLAST).

A “conservative substitution” is recognized in the art as a substitutionof one amino acid for another amino acid that has similar properties.Exemplary conservative substitutions are well known in the art (see,e.g., WO 97/09433, page 10, published Mar. 13, 1997; Lehninger,Biochemistry, Second Edition; Worth Publishers, Inc. NY: N.Y. (1975),pp. 71-′7′7; Lewin, Genes IV, Oxford University Press, NY and CellPress, Cambridge, Mass. (1990), p. 8).

“Inhibit” or “inhibited,” as used herein, refers to an alteration,reduction, down regulation or abrogation, directly or indirectly, in theexpression of a target gene or in the activity of a target molecule(e.g., thioesterase, acyl-CoA synthetase, alcohol dehydrogenase)relative to a control, endogenous or reference molecule, wherein thealteration, reduction, down regulation or abrogation is statistically,biologically, industrially, or clinically significant.

As used herein, the term “derivative” refers to a modification of acompound by chemical or biological means, with or without an enzyme,which modified compound is structurally similar to a parent compound and(actually or theoretically) derivable from that parent compound. Aderivative may have different chemical, biological or physicalproperties of the parent compound, such as being more hydrophilic orhaving altered reactivity as compared to the parent compound.Derivatization (i.e., modification) may involve substitution of one ormore moieties within the molecule (e.g., a change in functional group).For example, a hydrogen may be substituted with a halogen, such asfluorine or chlorine, or a hydroxyl group (—OH) may be replaced with acarboxylic acid moiety (—COOH). Other exemplary derivatizations includeglycosylation, alkylation, acylation, acetylation, ubiqutination,esterification, and amidation. As used herein, “fatty acid derivatives”include intermediates and products of the fatty acid biosynthesispathway found in cells, such as fatty acyl carrier proteins, activatedfatty acids (e.g., acyl or CoA containing), fatty aldehydes, fattyalcohols, fatty ester wax, hydroxy fatty acids, dicarboxylic acids,branched fatty acids, or the like.

The term “derivative” also refers to all solvates, for example, hydratesor adducts (e.g., adducts with alcohols), active metabolites, and saltsof the parent compound. The type of salt that may be prepared depends onthe nature of the moieties within the compound. For example, acidicgroups such as carboxylic acid groups can form alkali metal salts oralkaline earth metal salts (e.g., sodium salts, potassium salts,magnesium salts and calcium salts, and also salts with physiologicallytolerable quaternary ammonium ions and acid addition salts with ammoniaand physiologically tolerable organic amines such as, for example,triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine). Basic groupscan form acid addition salts, for example, with inorganic acids such ashydrochloric acid, sulfuric acid or phosphoric acid, or with organiccarboxylic acids and sulfonic acids such as acetic acid, citric acid,lactic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid,methanesulfonic acid orp-toluenesulfonic acid. Compounds thatsimultaneously contain a basic group and an acidic group, for example, acarboxyl group in addition to basic nitrogen atoms, can be present aszwitterions. Salts can be obtained by customary methods known to thoseskilled in the art, for example, by combining a compound with aninorganic or organic acid or base in a solvent or diluent, or from othersalts by cation exchange or anion exchange.

Compositions and Methods for Making Fatty Acid Derivatives

The C₁ metabolizing microorganisms used to produce fatty acidderivatives can be recombinantly modified to include nucleic acidsequences that express or over-express polypeptides of interest. Forexample, a C₁ metabolizing microorganism can be modified to increase theproduction of acyl-CoA and reduce the catabolism of fatty acidderivatives and intermediates in the fatty acid biosynthetic pathway,such as acyl-CoA, or to reduce feedback inhibition at specific points inthe fatty acid biosynthetic pathway. In addition to modifying the genesdescribed herein, additional cellular resources can be diverted toover-produce fatty acids, for example, the lactate, succinate or acetatepathways can be attenuated, and acetyl-CoA carboxylase (acc) can beover-expressed. The modifications to a C₁ metabolizing microorganismsdescribed herein can be through genomic alterations, addition ofrecombinant expression systems, or a combination thereof.

The fatty acid biosynthetic pathways involved are illustrated in FIGS. 1to 6. Different steps in the pathway are catalyzed by different enzymesand each step is a potential place for over-expression of the gene toproduce more enzyme and thus drive the production of more fatty acidsand fatty acid derivatives. Nucleic acid molecules encoding enzymesrequired for the pathway may also be recombinantly added to a C₁metabolizing microorganism lacking such enzymes. Finally, steps thatwould compete with the pathway leading to production of fatty acids andfatty acid derivatives can be attenuated or blocked in order to increasethe production of the desired products.

Fatty acid synthases (FASs) are a group of enzymes that catalyze theinitiation and elongation of acyl chains (Marrakchi et al., BiochemicalSociety 30:1050, 2002). The acyl carrier protein (ACP) along with theenzymes in the FAS pathway control the length, degree of saturation, andbranching of the fatty acids produced. The steps in this pathway arecatalyzed by enzymes of the fatty acid biosynthesis (fab) and acetyl-CoAcarboxylase (acc) gene families. Depending upon the desired product, oneor more of these genes can be attenuated, expressed or over-expressed(see FIGS. 1-6 for a depiction of the enzymatic activity of each enzymeand its enzyme classification number).

The fatty acid biosynthetic pathway in the production host uses theprecursors acetyl-CoA and malonyl-CoA (see, e.g., FIG. 1). The steps inthis pathway are catalyzed by enzymes of the fatty acid biosynthesis(fab) and acetyl-CoA carboxylase (acc) gene families. This pathway isdescribed in Heath et al., Prog. Lipid Res. 40:467, 2001.

Acetyl-CoA is carboxylated by acetyl-CoA carboxylase (Acc, amultisubunit enzyme encoded by four separate genes, accABCD), to formmalonyl-CoA. The malonate group is transferred to ACP by malonyl-CoA:ACPtransacylase (FabD) to form malonyl-ACP. A condensation reaction thenoccurs, where malonyl-ACP merges with acetyl-CoA, resulting inβ-ketoacyl-ACP. β-ketoacyl-ACP synthase III (FabH) initiates the FAScycle, while β-ketoacyl-ACP synthase I (FabB) and β-ketoacyl-ACPsynthase II (FabF) are involved in subsequent cycles.

Next, a cycle of steps is repeated until a saturated fatty acid of theappropriate length is made. First, the β-ketoacyl-ACP is reduced byNADPH to form β-hydroxyacyl-ACP. This step is catalyzed byβ-ketoacyl-ACP reductase (FabG). β-hydroxyacyl-ACP is then dehydrated toform trans-2-enoyl-ACP. β-hydroxyacyl-ACP dehydratase/isomerase (FabA)or β-hydroxyacyl-ACP dehydratase (FabZ) catalyzes this step.NADPH-dependent trans-2-enoyl-ACP reductase I, II, or III (Fabl, FabK,and FabL, respectively) reduces trans-2-enoyl-ACP to form acyl-ACP.Subsequent cycles are started by the condensation of malonyl-ACP withacyl-ACP by β-ketoacyl-ACP synthase I or β-ketoacyl-ACP synthase II(FabB and FabF, respectively).

C₁ metabolizing microorganisms as described herein may be engineered tooverproduce acetyl-CoA and malonyl-CoA. Several different modificationscan be made, either in combination or individually, to a C₁ metabolizingmicroorganism to obtain increased acetyl-CoA/malonyl-CoA/fatty acid andfatty acid derivative production. For example, to increase acetyl-CoAproduction, one or more of the following genes could be expressed in aC₁ metabolizing microorganism: pdh, panK, aceEF (encoding the E1pdehydrogenase component and the E2p dihydrolipoamide acyltransferasecomponent of the pyruvate and 2-oxoglutarate dehydrogenase complexes),fabH, fabD, fabG, acpP, or fabF. In other examples, additional DNAsequence encoding fatty-acyl-CoA reductases and aldehyde decarbonylasescould be expressed in a C₁ metabolizing microorganism. It is well knownin the art that a plasmid containing one or more of the aforementionedgenes, all under the control of a constitutive, or otherwisecontrollable promoter, can be constructed. Exemplary GenBank accessionnumbers for these genes are pdh (BAB34380, AAC73227, AAC73226), panK(also known as coaA, AAC76952), aceEF (AAC73227, AAC73226), fabH(AAC74175), fabD (AAC74176), fabG (AAC74177), acpP (AAC74178), fabF(AAC74179).

Additionally, the expression levels of fadE, gpsA, ldhA, pflb, adhE,pta, poxB, ackA, or ackB can be reduced, inhibited or knocked-out in theengineered microorganism by transformation with conditionallyreplicative or non-replicative plasmids containing null or deletionmutations of the corresponding genes, or by substituting promoter orenhancer sequences. Exemplary GenBank accession numbers for these genesare fadE (AAC73325), gspA (AAC76632), ldhA (AAC74462), pflb (AAC73989),adhE (AAC74323), pta (AAC75357), poxB (AAC73958), ackA (AAC75356), andackB (BAB81430). The resulting engineered C₁ metabolizing microorganismswill have increased acetyl-CoA production levels when grown in anappropriate environment, such as with a C₁ substrate feedstock.

Moreover, malonyl-CoA overproduction can be affected by engineering theC₁ metabolizing microorganisms as described herein with accABCD (e.g.,accession number AAC73296, EC 6.4.1.2) included in the plasmidsynthesized de novo. Fatty acid overproduction can be achieved byfurther including a nucleic acid molecule encoding lipase (e.g., GenbankAccession Nos. CAA89087, CAA98876) in the plasmid synthesized de novo.

As a result, in some examples, acetyl-CoA carboxylase is over-expressedto increase the intracellular concentration thereof by at least about2-fold, preferably at least about 5-fold, or more preferably at leastabout 10-fold, relative to native expression levels.

In some embodiments, the plsB (e.g., Genbank Accession No. AAC77011)D311E mutation can be used to increase the amount of available acyl-CoA.In further embodiments, over-expression of a sfa gene (suppressor ofFabA, e.g., Genbank Accession No. AAN79592) can be included in a C₁metabolizing microorganism to increase production of monounsaturatedfatty acids (Rock et al., J. Bacteriology 178:5382, 1996).

As described herein, acetyl-CoA and malonyl-CoA are processed in severalsteps to form acyl-ACP chains. The enzyme sn-glycerol-3-phosphateacyltransferase (PlsB) catalyzes the transfer of an acyl group fromacyl-ACP or acyl-CoA to the sn-1 position of glycerol-3-phosphate. Thus,PlsB is a key regulatory enzyme in phospholipid synthesis, which is partof the fatty acid pathway. Inhibiting PlsB leads to an increase in thelevels of long chain acyl-ACP, which feedback will inhibit early stepsin the pathway (e.g., accABCD, fabH, and fabI). Uncoupling of thisregulation, for example, by thioesterase overexpression leads toincreased fatty acid production. The tes and fat gene families expressthioesterase. FaI is also inhibited in vitro by long-chain acyl-CoA.

To engineer a C₁ metabolizing microorganism for the production of ahomogeneous or mixed population of fatty acid derivatives, one or moreendogenous genes can be attenuated, inhibited or functionally deletedand, as a result, one or more thioesterases can be expressed. Forexample, C₁₀ fatty acid derivatives can be produced by attenuatingthioesterase C₁₈ (e.g., Genbank Accession Nos. AAC73596 and POADA1),which uses C_(18:1)-ACP, and at the same time expressing thioesteraseC₁₀ (e.g., Genbank Accession No. Q39513), which uses C₁₀-ACP. Thisresults in a relatively homogeneous population of fatty acid derivativesthat have a carbon chain length of 10. In another example, C₁₄ fattyacid derivatives can be produced by attenuating endogenous thioesterasesthat produce non-C₁₄ fatty acids and expressing the thioesteraseaccession number Q39473 (which uses C₁₄-ACP). In yet another example,C₁₂ fatty acid derivatives can be produced by expressing thioesterasesthat use C₁₂-ACP (for example, Genbank Accession No. Q41635) andattenuating thioesterases that produce non-C₁₂ fatty acids. Acetyl-CoA,malonyl-CoA, and fatty acid overproduction can be verified using methodsknown in the art, for example by using radioactive precursors, HPLC, andGC-MS subsequent to cell lysis. Non-limiting examples of thioesterasesuseful in the claimed methods and C₁ metabolizing microorganisms of thisdisclosure are listed in Table 1 of U.S. Pat. No. 8,283,143, which tableis hereby incorporated by reference in its entirety.

Acyl-CoA synthase (ACS) esterifies free fatty acids to acyl-CoA by atwo-step mechanism. The free fatty acid first is converted to anacyl-AMP intermediate (an adenylate) through the pyrophosphorolysis ofATP. The activated carbonyl carbon of the adenylate is then coupled tothe thiol group of CoA, releasing AMP and the acyl-CoA final product.See Shockey et al., Plant. Physiol. 129:1710, 2002.

The E. coli ACS enzyme FadD and the fatty acid transport protein FadLare essential components of a fatty acid uptake system. FadL mediatestransport of fatty acids into the bacterial cell, and FadD mediatesformation of acyl-CoA esters. When no other carbon source is available,exogenous fatty acids are taken up by bacteria and converted to acyl-CoAesters, which bind to the transcription factor FadR and derepress theexpression of the fad genes that encode proteins responsible for fattyacid transport (FadL), activation (FadD), and β-oxidation (FadA, FadB,FadE, and FadH). When alternative sources of carbon are availablebacteria synthesize fatty acids as acyl-ACPs, which are used forphospholipid synthesis, but are not substrates for β-oxidation. Thus,acyl-CoA and acyl-ACP are both independent sources of fatty acids thatwill result in different end-products. See Caviglia et al., J. Biol.Chem. 279:1163, 2004.

C₁ metabolizing microorganisms can be engineered using nucleic acidmolecules encoding known polypeptides to produce fatty acids of variouslengths, which can then be converted to acyl-CoA and ultimately to fattyacid derivatives, such as fatty alcohol. One method of making fatty acidderivatives involves increasing the expression, or expressing moreactive forms, of one or more acyl-CoA synthase peptides (EC 6.2.1.-). Alist of acyl-CoA synthases that can be expressed to produce acyl-CoA andfatty acid derivatives is shown in Table 2 of U.S. Pat. No. 8,283,143,which table is hereby incorporated by reference in its entirety. Theseacyl-CoA synthases can be used to improve any pathway that usesfatty-acyl-CoAs as substrates.

Acyl-CoA is reduced to a fatty aldehyde by NADH-dependent acyl-CoAreductase (e.g., Acr1). The fatty aldehyde is then reduced to a fattyalcohol by NADPH-dependent alcohol dehydrogenase (e.g., YqhD).Alternatively, fatty alcohol forming acyl-CoA reductase (FAR) catalyzesthe reduction of an acyl-CoA into a fatty alcohol and CoASH. FAR usesNADH or NADPH as a cofactor in this four-electron reduction. Althoughthe alcohol-generating FAR reactions proceed through an aldehydeintermediate, a free aldehyde is not released. Thus, alcohol-formingFARs are distinct from those enzymes that carry out two-electronreductions of acyl-CoA and yield free fatty aldehyde as a product. (SeeCheng and Russell, J. Biol. Chem., 279:37789, 2004; Metz et al., PlantPhysiol. 122:635, 2000).

C₁ metabolizing microorganisms can be engineered using knownpolypeptides to produce fatty alcohols from acyl-CoA. One method ofmaking fatty alcohols involves increasing the expression of, orexpressing more active forms of, fatty alcohol forming acyl-CoAreductases (encoded by a gene such as acr1 from FAR, EC 1.2.1.50/1.1.1)or acyl-CoA reductases (EC 1.2.1.50) and alcohol dehydrogenase (EC1.1.1.1). Exemplary GenBank Accession Numbers are listed in FIG. 1 ofU.S. Pat. No. 8,283,143, which figure is hereby incorporated byreference in its entirety.

Fatty alcohols can be described as hydrocarbon-based surfactants. Forsurfactant production, a C₁ metabolizing microorganism is modified sothat it produces a surfactant from a C₁ substrate feedstock. Such a C₁metabolizing microorganism includes a first exogenous nucleic acidmolecule encoding a protein capable of converting a fatty acid to afatty aldehyde and a second exogenous nucleic acid molecule encoding aprotein capable of converting a fatty aldehyde to an alcohol. In someexamples, a first exogenous nucleic acid molecule encodes a fatty acidreductase (FAR). In one embodiment, a second exogenous nucleic acidmolecule encodes mammalian microsomal aldehyde reductase or long-chainaldehyde dehydrogenase. In a further example, first and second exogenousnucleic acid molecules are from Arthrobacter AK 19, Rhodotorulaglutinins, Acinetobacter sp. M-1, or Candida hpolytica. In oneembodiment, first and second heterologous nucleic acid molecules arefrom a multienzyme complex from Acinetobacter sp. M-1 or Candidalipolytica.

Additional sources of heterologous nucleic acid molecules encoding fattyacid to long chain alcohol converting proteins that can be used insurfactant production include Mortierella alpina (ATCC 32222),Cryptococcus curvatus, (also referred to as Apiotricum curvatum),Akanivorax jadensis (T9T=DSM 12718=ATCC 700854), Acinetobacter sp.HO1-N(ATCC 14987) and Rhodococcus opacus (PD630 DSMZ 44193).

In one example, a fatty acid derivative is a saturated or unsaturatedsurfactant product having a carbon chain length of about 8 to about 24carbon atoms, about 8 to about 18 carbon atoms, about 8 to about 14carbon atoms, about 10 to about 18 carbon atoms, or about 12 to about 16carbon atoms. In another example, the surfactant product has a carbonchain length of about 10 to about 14 carbon atoms, or about 12 to about14 carbon atoms.

Appropriate C₁ metabolizing microorganisms for producing surfactants canbe either eukaryotic or prokaryotic microorganisms. C₁ metabolizingmicroorganisms that demonstrate an innate ability to synthesize highlevels of surfactant precursors from C₁ feedstock in the form of fattyacid derivatives, such as methanogens engineered to express acetyl CoAcarboxylase are used.

Production hosts can be engineered using known polypeptides to producefatty esters of various lengths. One method of making fatty estersincludes increasing the expression of, or expressing more active formsof, one or more alcohol O-acetyltransferase peptides (EC 2.3.1.84).These peptides catalyze the acetylation of an alcohol by converting anacetyl-CoA and an alcohol to a CoA and an ester. In some examples, thealcohol O-acetyltransferase peptides can be expressed in conjunctionwith selected thioesterase peptides, FAS peptides, and fatty alcoholforming peptides, thus allowing the carbon chain length, saturation, anddegree of branching to be controlled. In some cases, a bkd operon can becoexpressed to enable branched fatty acid precursors to be produced.

As used herein, alcohol O-acetyltransferase peptides include peptides inenzyme classification number EC 2.3.1.84, as well as any other peptidecapable of catalyzing the conversion of acetyl-CoA and an alcohol toform a CoA and an ester. Additionally, one of ordinary skill in the artwill appreciate that alcohol O-acetyltransferase peptides will catalyzeother reactions.

For example, some alcohol O-acetyltransferase peptides will accept othersubstrates in addition to fatty alcohols or acetyl-CoA thioester, suchas other alcohols and other acyl-CoA thioesters. Such non-specific ordivergent-specificity alcohol O-acetyltransferase peptides are,therefore, also included. Alcohol O-acetyltransferase peptide sequencesare publicly available and exemplary GenBank Accession Numbers arelisted in FIG. 1 of U.S. Pat. No. 8,283,143, which figure is herebyincorporated by reference in its entirety. Assays for characterizing theactivity of particular alcohol O-acetyltransferase peptides are wellknown in the art. O-acyltransferases can be engineered to have newactivities and specificities for the donor acyl group or acceptoralcohol moiety. Engineered enzymes can be generated throughwell-documented rational and evolutionary approaches.

Fatty esters are synthesized by acyl-CoA:fatty alcohol acyltransferase(e.g., ester synthase), which conjugate a long chain fatty alcohol to afatty acyl-CoA via an ester linkage. Ester synthases and encoding genesare known from the jojoba plant and the bacterium Acinetobacter sp. ADP1(formerly Acinetobacter calcoaceticus ADP1). The bacterial estersynthase is a bifunctional enzyme, exhibiting ester synthase activityand the ability to form triacylglycerols from diacylglycerol substratesand fatty acyl-CoAs (acyl-CoA:diglycerol acyltransferase (DGAT)activity). The gene wax/dgat encodes both ester synthase and DGAT. SeeCheng et al., J. Biol. Chem. 279:37798, 2004; Kalscheuer andSteinbuchel, J. Biol. Chem. 278:8075, 2003. Ester synthases may also beused to produce certain fatty esters.

The production of fatty esters, including waxes, from acyl-CoA andalcohols, can be engineered using known polypeptides. One method ofmaking fatty esters includes increasing the expression of, or expressingmore active forms of, one or more ester synthases (EC 2.3.1.20,2.3.1.75). Ester synthase peptide sequences are publicly available andexemplary GenBank Accession Numbers are listed in FIG. 1 of U.S. Pat.No. 8,283,143, which figure is hereby incorporated by reference in itsentirety. Methods to identify ester synthase activity are provided inU.S. Pat. No. 7,118,896.

In particular examples, if a desired product is a fatty acid ester wax,a C₁ metabolizing microorganism is modified so that it produces anester. Such a C₁ metabolizing microorganism includes an exogenousnucleic acid molecule encoding an ester synthase that is expressed so asto confer upon a C₁ metabolizing microorganism the ability to synthesizea saturated, unsaturated, or branched fatty ester from a C₁ substratefeedstock. In some embodiments, a C₁ metabolizing microorganism can alsoexpress nucleic acid molecules encoding the following exemplaryproteins: fatty acid elongases, acyl-CoA reductases, acyltransferases,ester synthases, fatty acyl transferases, diacylglycerolacyltransferases, acyl-coA wax alcohol acyltransferases, or anycombination thereof. In an alternate embodiment, C₁ metabolizingmicroorganisms comprises a nucleic acid molecule encoding a bifunctionalester synthase/acyl-CoA: diacylglycerol acyltransferase. For example,the bifunctional ester synthase/acyl-CoA:diacylglycerol acyltransferasecan be selected from the multienzyme complexes from Simmondsiachinensis, Acinetobacter sp. ADP1 (formerly Acinetobacter calcoaceticusADP1), Alcanivorax borkumensis, Pseudomonas aeruginosa, Fundibacterjadensis, Arabidopsis thaliana, or Alcaligenes eutrophus (later renamedRalstonia eutropha). In one embodiment, fatty acid elongases, acyl-CoAreductases or wax synthases are from a multienzyme complex fromRalstonia eutropha or other organisms known in the literature to produceesters, such as wax or fatty esters.

Additional sources of heterologous nucleic acid molecules encoding estersynthesis proteins useful in fatty ester production include Mortierellaalpina (e.g., ATCC 32222), Cryptococcus curvatus (also referred to asApiotricum curvatum), Alcanivorax jadensis (for example, T9T=DSM12718=ATCC 700854), Acinetobacter sp. HO1-N(e.g., ATCC 14987), andRhodococcus opacus (e.g., PD630, DSMZ 44193). In one example, the estersynthase from Acinetobacter sp. ADP1 at locus AA017391 (described inKalscheuer and Steinbuchel, J. Biol. Chem. 278:8075, 2003) is used. Inanother example, an ester synthase from Simmondsia chinensis at locusAAD38041 is used.

Optionally, an ester exporter such as a member of the FATP family can beused to facilitate the release of esters into the extracellularenvironment. A non-limiting example of an ester exporter that can beused is fatty acid (long chain) transport protein CG7400-PA, isoform A,from Drosophila melanogaster, at locus NP 524723.

Transport proteins export fatty acid derivatives out of a C₁metabolizing microorganism. Many transport and efflux proteins serve toexcrete a large variety of compounds, and can naturally be modified tobe selective for particular types of fatty acid derivatives.Non-limiting examples of suitable transport proteins are ATP-BindingCassette (ABC) transport proteins, efflux proteins, and fatty acidtransporter proteins (FATP). Additional non-limiting examples ofsuitable transport proteins include the ABC transport proteins fromorganisms such as Caenorhabditis elegans, Arabidopsis thalania,Alkaligenes eutrophus, Rhodococcus erythropolis. Exemplary ABC transportproteins which could be used are CER5, AtMRP5, AmiS2, or AtPGP1. In apreferred embodiment, an ABC transport protein is CER5 (e.g., AY734542).Vectors containing genes that express suitable transport proteins can beinserted into the protein production host to increase the release offatty acid derivatives.

C₁ metabolizing microorganisms can also be chosen for their endogenousability to release fatty acid derivatives. The efficiency of productproduction and release into the fermentation broth can be expressed as aratio of intracellular product to extracellular product. In someexamples, the ratio can be about 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4,or 1.5.

Fatty acid derivatives with particular branch points, levels ofsaturation, carbon chain length, and ester characteristics can beproduced as desired. C₁ metabolizing microorganisms that naturallyproduce particular derivatives can be chosen as the initial host cell.Alternatively, genes that express enzymes that will produce particularfatty acid derivatives can be inserted into a C₁ metabolizingmicroorganism as described herein.

In some examples, the expression of exogenous FAS genes originating fromdifferent species or engineered variants can be introduced into a C₁metabolizing microorganism to allow for the biosynthesis of fatty acidsthat are structurally different (in length, branching, degree ofunsaturation, etc.) from those of the native host cell. Theseheterologous gene products can also be chosen or engineered to beunaffected by the natural regulatory mechanisms in the host cell, andtherefore allow for control of the production of the desired commercialproduct. For example, FAS enzymes from Bacillus subtilis, Saccharomycescerevisiae, Streptomyces spp., Ralstonia, Rhodococcus, Corynebacteria,Brevibacteria, Mycobacteria, oleaginous yeast, or the like can beexpressed in a C₁ metabolizing microorganism. The expression of suchexogenous enzymes will alter the structure of the fatty acid producedand ultimately the fatty acid derivative.

When a C₁ metabolizing microorganism is engineered to produce a fattyacid with a specific level of unsaturation, branching, or carbon chainlength, the resulting engineered fatty acid can be used in theproduction of fatty acid derivatives. Fatty acid derivatives generatedfrom such C₁ metabolizing microorganisms can display the characteristicsof the engineered fatty acid.

For example, a production host can be engineered to make branched, shortchain fatty acids, which may then be used by the production host toproduce branched, short chain fatty alcohols. Similarly, a hydrocarboncan be produced by engineering a production host to produce a fatty acidhaving a defined level of branching, unsaturation, or carbon chainlength; thus, producing a homogeneous hydrocarbon population. Additionalsteps can be employed to improve the homogeneity of the resultingproduct. For example, when an unsaturated alcohol, fatty ester, orhydrocarbon is desired, a C₁ metabolizing microorganism can beengineered to produce low levels of saturated fatty acids and inaddition can be modified to express an additional desaturase to lessenor reduce the production of a saturated product.

Fatty acids are a key intermediate in the production of fatty acidderivatives. Fatty acid derivatives can be produced to contain branchpoints, cyclic moieties, and combinations thereof, by using branched orcyclic fatty acids to make the fatty acid derivatives.

For example, C₁ metabolizing microorganisms may naturally producestraight chain fatty acids. To engineer C₁ metabolizing microorganismsto produce branched chain fatty acids, several genes that providebranched precursors (e.g., bkd operon) can be introduced into a C₁metabolizing microorganism (e.g., methanogen) and expressed to allowinitiation of fatty acid biosynthesis from branched precursors (e.g.,fabH). The bkd, ilv, icm, and fab gene families may be expressed orover-expressed to produce branched chain fatty acid derivatives.Similarly, to produce cyclic fatty acids, genes that provide cyclicprecursors can be introduced into the production host and expressed toallow initiation of fatty acid biosynthesis from cyclic precursors. Theans, chc, and plm gene families may be expressed or over-expressed toproduce cyclic fatty acids. Non-limiting examples of genes in these genefamilies that may be used in the present methods and C₁ metabolizingmicroorganisms of this disclosure are listed in U.S. Pat. No. 8,283,143(FIG. 1, which figure is herein incorporated by reference).

Additionally, the production host can be engineered to express genesencoding proteins for the elongation of branched fatty acids (e.g., ACP,FabF, etc.) or to delete or attenuate the corresponding genes thatnormally lead to straight chain fatty acids. In this regard, endogenousgenes that would compete with the introduced genes (e.g., fabH, fabF)are deleted, inhibited or attenuated.

The branched acyl-CoA (e.g., 2-methyl-butyryl-CoA, isovaleryl-CoA,isobutyryl-CoA, etc.) are the precursors of branched fatty acids. Inmost microorganisms containing branched fatty acids, the branched fattyacids are synthesized in two steps from branched amino acids (e.g.,isoleucine, leucine, and valine) (Kadena, Microbial. Rev. 55:288, 1991).A C₁ metabolizing microorganism can be engineered to express orover-express one or more of the enzymes involved in these two steps toproduce branched fatty acid derivatives, or to over-produce branchedfatty acid derivatives. For example, a C₁ metabolizing microorganism mayhave an endogenous enzyme that can accomplish one step leading tobranched fatty acid derivative; therefore, only genes encoding enzymesinvolved in the second step need to be introduced recombinantly.

The first step in forming branched fatty acid derivatives is theproduction of the corresponding α-keto acids by a branched-chain aminoacid aminotransferase. C₁ metabolizing microorganisms, such asmethanotrophs, may endogenously include genes encoding such enzymes orsuch genes may be recombinantly introduced. In some C₁ metabolizingmicroorganisms, a heterologous branched-chain amino acidaminotransferase may not be expressed. Hence, in certain embodiments,IlvE from E. coli or any other branched-chain amino acidaminotransferase (e.g., IlvE from Lactococcus lactis (GenBank accessionAAF34406), IlvE from Pseudomonas putida (GenBank accession NP_745648),or IlvE from Streptomyces coelicolor (GenBank accession NP_629657)) canbe introduced into C₁ metabolizing microorganisms of this disclosure. Ifthe aminotransferase reaction is rate limiting in branched fatty acidbiosynthesis in the chosen C₁ metabolizing microorganism, then anaminotransferase can be over-expressed.

The second step is the oxidative decarboxylation of the α-ketoacids tothe corresponding branched-chain acyl-CoA. This reaction can becatalyzed by a branched-chain α-keto acid dehydrogenase complex (bkd; EC1.2.4.4) (Denoya et al., J. Bacteriol. 177:3504, 1995), which includesE1α/β (decarboxylase), E2 (dihydrolipoyl transacylase) and E3(dihydrolipoyl dehydrogenase) subunits. These branched-chain α-keto aciddehydrogenase complexes are similar to pyruvate and α-ketoglutaratedehydrogenase complexes. Every microorganism that possesses branchedfatty acids or grows on branched-chain amino acids can be used as asource to isolate bkd genes for expression in C₁ metabolizingmicroorganisms, such as methanotrophs. Furthermore, if the C₁metabolizing microorganism has an E3 component as part of its pyruvatedehydrogenase complex (lpd, EC 1.8.1.4), then it may be sufficient toonly express the E1α/β and E2 bkd genes.

In another example, isobutyryl-CoA can be made in a C₁ metabolizingmicroorganism, for example, in a methanotroph, through the coexpressionof a crotonyl-CoA reductase (Ccr, EC 1.6.5.5, 1.1.1.1) andisobutyryl-CoA mutase (large subunit IcmA, EC 5.4.99.2; small subunitIcmB, EC 5.4.99.2) (Han and Reynolds, J. Bacteriol. 179:5157, 1997).Crotonyl-CoA is an intermediate in fatty acid biosynthesis in E. coliand other microorganisms.

In addition to expression of the bkd genes, the initiation of brFAbiosynthesis utilizes β-ketoacyl-acyl-carrier-protein synthase III(FabH, EC 2.3.1.41) with specificity for branched chain acyl-CoAs (Li etal., J. Bacteriol. 187:3795, 2005). A fabH gene that is involved infatty acid biosynthesis of any branched fatty acid-containingmicroorganism can be expressed in a C₁ metabolizing microorganism ofthis disclosure. The Bkd and FabH enzymes from production hosts that donot naturally make branched fatty acids or derivatives thereof may notsupport branched fatty acid production; therefore, Bkd and FabH can beexpressed recombinantly. Vectors containing the bkd and fabH genes canbe inserted into such a C₁ metabolizing microorganism. Similarly, theendogenous level of Bkd and FabH production may not be sufficient toproduce branched fatty acid derivatives, so in certain embodiments theyare over-expressed. Additionally, other components of the fatty acidbiosynthesis pathway can be expressed or over-expressed, such as acylcarrier proteins (ACPs) and β-ketoacyl-acyl-carrier-protein synthase II(fabF, EC 2.3.1.41). In addition to expressing these genes, some genesin the endogenous fatty acid biosynthesis pathway may be attenuated inthe C₁ metabolizing microorganisms of this disclosure. Genes encodingenzymes that would compete for substrate with the enzymes of the pathwaythat result in brFA production may be attenuated or inhibited toincrease branched fatty acid derivative production.

As mentioned above, branched chain alcohols can be produced through thecombination of expressing genes that support branched fatty acidsynthesis and alcohol synthesis. For example, when an alcohol reductase,such as Acr1 from Acinetobacter baylyi ADP1, is coexpressed with a bkdoperon, C₁ metabolizing microorganisms of this disclosure can synthesizeisopentanol, isobutanol or 2-methyl butanol. Similarly, when Acr1 iscoexpressed with ccr/icm genes, C₁ metabolizing microorganisms of thisdisclosure can synthesize isobutanol.

To convert a C₁ metabolizing microorganisms of this disclosure, such asa methanotroph, into an organism capable of synthesizing w-cyclic fattyacids (cyFA), a gene that provides the cyclic precursorcyclohexylcarbonyl-CoA (CHC-CoA) (Cropp et al., Nature Biotech. 18:980,2000) is introduced and expressed in the C₁ metabolizing microorganismsof this disclosure.

Non-limiting examples of genes that provide CHC-CoA include ansJ, ansK,ansL, chcA and ansM from the ansatrienin gene cluster of Streptomycescollinus (Chen et al., Eur. J. Biochem. 261:98, 1999) or plmJ, plmK,plmL, chcA and plmM from the phoslactomycin B gene cluster ofStreptomyces sp. HK803 (Palaniappan et al., J. Biol. Chem. 278:35552,2003) together with the chcB gene (Patton et al., Biochem. 39:7595,2000) from S. collinus, S. avermitilis or S. coelicolor. The FabH, ACPand fabF genes can be expressed to allow initiation and elongation ofco-cyclic fatty acids. Alternatively, the homologous genes can beisolated from microorganisms that make cyFA and expressed in C₁metabolizing microorganisms of this disclosure.

The genes fabH, acp and fabF are sufficient to allow initiation andelongation of ω-cyclic fatty acids because they can have broad substratespecificity. If the coexpression of any of these genes with theansJKLM/chcAB or pmlJKLM/chcAB genes does not yield cyFA, then fabH, acpor fabF homologs from microorganisms that make cyFAs can be isolated(e.g., by using degenerate PCR primers or heterologous DNA sequenceprobes) and co-expressed.

Fatty acids are a key intermediate in the production of fatty acidderivatives. The degree of saturation in fatty acid derivatives can becontrolled by regulating the degree of saturation of the fatty acidintermediates. The sfa, gns, and fab families of genes can be expressedor over-expressed to control the saturation of fatty acids. Non-limitingexamples of genes in these gene families that may be used in the presentmethods, and with C₁ metabolizing microorganisms of this disclosure, arelisted in FIG. 1 of U.S. Pat. No. 8,283,143, which figure is hereinincorporated by reference in its entirety.

C₁ metabolizing microorganisms of this disclosure can be engineered toproduce unsaturated fatty acid derivatives by engineering the C₁metabolizing microorganisms (e.g., methanotrophs) to over-express fabB,or by growing the C₁ metabolizing microorganism at low temperatures(e.g., less than 37° C.). In E. coli, FabB has preference tocisΔ³decenoyl-ACP and results in unsaturated fatty acid production.Over-expression of FabB results in the production of a significantpercentage of unsaturated fatty acids (de Mendoza et al., J. Biol. Chem.258:2098, 1983). A nucleic acid molecule encoding a fabB may be insertedinto and expressed in C₁ metabolizing microorganisms (e.g.,methanotrophs) not naturally having the gene. These unsaturated fattyacids can then be used as intermediates in C₁ metabolizingmicroorganisms that are engineered to produce fatty acid derivatives,such as fatty alcohols, fatty esters, waxes, hydroxy fatty acids,dicarboxylic acids, or the like.

Alternatively, a repressor of fatty acid biosynthesis, for example, fabRcan be inhibited or deleted in C₁ metabolizing microorganisms (e.g.,methanotrophs), which may also result in increased unsaturated fattyacid production as is seen in E. coli (Zhang et al., J. Biol. Chem.277:15558, 2002). Further increase in unsaturated fatty acids may beachieved, for example, by over-expression of fabM (trans-2,cis-3-decenoyl-ACP isomerase) and controlled expression of fabK(trans-2-enoyl-ACP reductase II) from Streptococcus pneumoniae(Marrakchi et al., J. Biol. Chem. 277:44809, 2002), while deleting fabI(trans-2-enoyl-ACP reductase). Additionally, to increase the percentageof unsaturated fatty esters, a C₁ metabolizing microorganism (e.g.,methanotroph) can also over-express fabB (encoding β-ketoacyl-ACPsynthase I, Accession No. EC:2.3.1.41), sfa (encoding a suppressor offabA), and gnsA and gnsB (both encoding secG null mutant suppressors,i.e., cold shock proteins). In some examples, an endogenous fabF genecan be attenuated, which can increase the percentage of palmitoleate(C_(16:1)) produced.

In another example, a desired fatty acid derivative is a hydroxylatedfatty acid. Hydroxyl modification can occur throughout the chain usingspecific enzymes. In particular, ω-hydroxylation produces a particularlyuseful molecule containing functional groups at both ends of themolecule (e.g., allowing for linear polymerization to produce polyesterplastics). In certain embodiments, a C₁ metabolizing microorganism(e.g., methanotroph) may comprise one or more modified CYP52A typecytochrome P450 selected from CYP52A13, CYP52A14, CYP52A17, CYP52A18,CYP52A12, and CYP52A12B, wherein the cytochrome modifies fatty acidsinto, for example, w-hydroxy fatty acids. Different fatty acids arehydroxylated at different rates by different cytochrome P450s. Toachieve efficient hydroxylation of a desired fatty acid feedstock, C₁metabolizing microorganisms are generated to express one or more P450enzymes that can ω-hydroxylate a wide range of highly abundant fattyacid substrates. Of particular interest are P450 enzymes that catalyzeω-hydroxylation of lauric acid (C_(12:0)), myristic acid (C_(14:0)),palmitic acid (C_(16:0)), stearic acid (C_(18:0)), oleic acid(C_(18:1)), linoleic acid (C_(18:2)), and α-linolenic acid (ω3,C_(18:3)). Examples of P450 enzymes with known ω-hydroxylation activityon different fatty acids that may be cloned into a C₁ metabolizingnon-photosynthetic microorganism include CYP94A1 from Vicia sativa(Tijet et al., Biochem. J. 332:583, 1988); CYP 94A5 from Nicotianatabacum (Le Bouquin et al., Eur. J. Biochem. 268:3083, 2001); CYP78A1from Zea mays (Larkin, Plant Mol. Biol. 25:343, 1994); CYP 86A1(Benveniste et al., Biochem. Biophys. Res. Commun. 243:688, 1998) andCYP86A8 (Wellesen et al., Proc. Nat'l. Acad. Sci. USA 98:9694, 2001)from Arabidopsis thaliana; CYP 92B1 from Petunia hybrida(Petkova-Andonova et al., Biosci. Biotechnol. Biochem. 66:1819, 2002);CYP102A1 (BM-3) mutant F87 from Bacillus megaterium (Oliver et al.,Biochem. 36:1567, 1997); and CYP 4 family from mammal and insect(Hardwick, Biochem. Pharmacol. 75:2263, 2008).

In certain embodiments, a C₁ metabolizing non-photosyntheticmicroorganisms comprises a nucleic acid molecule encoding a P450 enzymecapable of introducing additional internal hydroxylation at specificsites of fatty acids or ω-hydroxy fatty acids, wherein the recombinantC₁ metabolizing microorganisms can produce internally oxidized fattyacids or ω-hydroxy fatty acids or aldehydes or dicarboxylic acids.Examples of P450 enzymes with known in-chain hydroxylation activity ondifferent fatty acids that may be used in C₁ metabolizing microorganismsof this disclosure include CYP81B1 from Helianthus tuberosus with ω-1 toω-5 hydroxylation (Cabello-Hurtado et al., J. Biol. Chem. 273:7260,1998); CYP790C1 from Helianthus tuberosus with ω-1 and ω-2 hydroxylation(Kandel et al., J. Biol. Chem. 280:35881, 2005); CYP726A1 from Euphorbialagscae with epoxidation on fatty acid unsaturation (Cahoon et al.,Plant Physiol. 128:615, 2002); CYP152B1 from Sphingomonas paucimobiliswith α-hydroxylation (Matsunaga et al., Biomed. Life Sci. 35:365, 2000);CYP2E1 and 4A1 from human liver with ω-1 hydroxylation (Adas et al., J.Lip. Res. 40:1990, 1999); P450_(Bsp) from Bacillus substilis with α- andβ-hydroxylation (Lee et al., J. Biol. Chem. 278:9761, 2003); andCYP102A1 (BM-3) from Bacillus megaterium with ω-1, ω-2 and ω-3hydroxylation (Shirane et al., Biochem. 32:13732, 1993).

In certain embodiments, a C₁ metabolizing non-photosyntheticmicroorganisms comprises a nucleic acid molecule encoding a P450 enzymecapable of modifying fatty acids to comprise a ω-hydroxylation can befurther modified to further oxidize the ω-hydroxy fatty acid derivativeto yield dicarboxylic acids. In many cases, a P450 enzyme capable ofperforming the hydroxylation in the first instance is also capable ofperforming further oxidation to yield a dicarboxylic acid. In otherembodiments, non-specific native alcohol dehydrogenases in the hostorganism may oxidize the ω-hydroxy fatty acid to a dicarboxylic acid. Infurther embodiments, a C₁ metabolizing non-photosynthetic organismfurther comprises a nucleic acid molecule that encodes one or more fattyalcohol oxidases, (such as FAO1, FAO1B, FAO2, FAO2B) or alcoholdehydrogenases (such as ADH-A4, ADH-A4B, ADH-B4, ADH-B4B, ADH-A10 andADH-B11) (e.g., from Candida tropicalis as listed in U.S. PatentApplication Publication 2010/0291653, which list is incorporated hereinin its entirety) to facilitate production of dicarboxylic acids.

The methods described herein permit production of fatty esters and fattyacid derivatives having varied carbon chain lengths. Chain length iscontrolled by thioesterase, which is produced by expression of the tesand fat gene families. By expressing specific thioesterases, fatty acidderivatives having a desired carbon chain length can be produced.Non-limiting examples of suitable thioesterases are described herein andlisted in U.S. Pat. No. 8,283,143 (FIG. 1, which figure is hereinincorporated by reference). A nucleic acid molecule encoding aparticular thioesterase may be introduced into a C₁ metabolizingmicroorganism (e.g., methanotroph) so that a fatty acid derivative of aparticular carbon chain length is produced. In certain embodiments,expression of endogenous thioesterases are inhibited, suppressed, ordown-regulated.

In certain embodiments, a fatty acid derivative has a carbon chain ofabout 8 to 24 carbon atoms, about 8 to 18 carbon atoms, about 10 to 18carbon atoms, about 10 to 16 carbon atoms, about 12 to 16 carbon atoms,about 12 to 14 carbon atoms, about 14 to 24 carbon atoms, about 14 to 18carbon atoms, about 8 to 16 carbon atoms, or about 8 to 14 carbon atoms.In alternative embodiments, a fatty acid derivative has a carbon chainof less than about 20 carbon atoms, less than about 18 carbon atoms,less than about 16 carbon atoms, less than about 14 carbon atoms, orless than about 12 carbon atoms. In other embodiments, a fatty esterproduct is a saturated or unsaturated fatty ester product having acarbon atom content between 8 and 24 carbon atoms. In furtherembodiments, a fatty ester product has a carbon atom content between 8and 14 carbon atoms. In still further embodiments, a fatty ester producthas a carbon content of 14 and 20 carbons. In yet other embodiments, afatty ester is the methyl ester of C_(18:1). In further embodiments, afatty ester is the ethyl ester of C_(16:1). In other embodiments, afatty ester is the methyl ester of C_(16:1). In yet other embodiments, afatty ester is octadecyl ester of octanol.

Some microorganisms preferentially produce even- or odd-numbered carbonchain fatty acids and fatty acid derivatives. For example, E. colinormally produce even-numbered carbon chain fatty acids and fatty acidethyl esters (FAEE). In certain embodiments, the methods disclosedherein may be used to alter that production in C₁ metabolizingmicroorganisms (e.g., methanotrophs) such that C₁ metabolizingmicroorganisms (e.g., methanotrophs) can be made to produce odd-numberedcarbon chain fatty acid derivatives.

An ester includes what may be designated an “A” side and a “B” side. TheB side may be contributed by a fatty acid produced from de novosynthesis in a C₁ metabolizing microorganism (e.g., methanotroph) ofthis disclosure. In some embodiments where a C₁ metabolizingmicroorganism (e.g., methanotroph) is additionally engineered to makealcohols, including fatty alcohols, the A side is also produced by a C₁metabolizing microorganism (e.g., methanotroph). In yet otherembodiments, the A side can be provided in the medium. By selecting adesired thioesterase encoding nucleic acid molecule, a B side (and an Aside when fatty alcohols are being made) can be designed to be havecertain carbon chain characteristics. These characteristics includepoints of branching, unsaturation, and desired carbon chain lengths.

When particular thioesterase genes are selected, the A and B side willhave similar carbon chain characteristics when they are both contributedby a C₁ metabolizing microorganism (e.g., methanotroph) using fatty acidbiosynthetic pathway intermediates. For example, at least about 50%,60%, 70%, or 80% of the fatty esters produced will have A sides and Bsides that vary by about 2, 4, 6, 8, 10, 12, or 14 carbons in length.The A side and the B side can also display similar branching andsaturation levels.

In addition to producing fatty alcohols for contribution to the A side,a C₁ metabolizing microorganism (e.g., methanotroph) can produce othershort chain alcohols, such as ethanol, propanol, isopropanol,isobutanol, and butanol for incorporation on the A side. For example,butanol can be made by a C₁ metabolizing microorganism (e.g.,methanotroph). To create butanol producing cells, a C₁ metabolizingmicroorganism (e.g., methanotroph), for example, can be furtherengineered to express atoB (acetyl-CoA acetyltransferase) fromEscherichia coli K12, β-hydroxybutyryl-CoA dehydrogenase fromButyrivibrio fibrisolvens, crotonase from Clostridium beijerinckii,butyryl CoA dehydrogenase from Clostridium beijerinckii, CoA-acylatingaldehyde dehydrogenase (ALDH) from Cladosporium fulvum, and adhEencoding an aldehyde-alcohol dehydrogenase of Clostridium acetobutylicumin, for example, a pBAD24 expression vector under a prpBCDE promotersystem. C₁ metabolizing microorganisms (e.g., methanotrophs) may besimilarly modified to produce other short chain alcohols. For example,ethanol can be produced in a production host using the methods taught byKalscheuer et al. (Microbiol. 152:2529, 2006).

C₁ Metabolizing Microorganisms—Host Cells

The C₁ metabolizing microorganisms of the instant disclosure may be anatural strain, strain adapted (e.g., performing fermentation to selectfor strains with improved growth rates and increased total biomass yieldcompared to the parent strain), or recombinantly modified to producefatty acid derivatives of interest or to have increased growth rates orboth (e.g., genetically altered to express a fatty acyl-CoA reductase, athioesterase, acyl-CoA synthetase, or a combination thereof). In certainembodiments, the C₁ metabolizing microorganisms are not photosyntheticmicroorganisms, such as algae or plants.

In certain embodiments, the present disclosure provides C₁ metabolizingmicroorganisms that are prokaryotes or bacteria, such as Methylomonas,Methylobacter, Methylococcus, Methylosinus, Methylocystis,Methylomicrobium, Methanomonas, Methylophilus, Methylobacillus,Methylobacterium, Hyphomicrobium, Xanthobacter, Bacillus, Paracoccus,Nocardia, Arthrobacter, Rhodopseudomonas, or Pseudomonas.

In further embodiments, the C₁ metabolizing bacteria are a methanotrophor a methylotroph. Exemplary methanotrophs include Methylomonas,Methylobacter, Methylococcus, Methylosinus, Methylocystis,Methylomicrobium, Methanomonas, Methylocella, or a combination thereof.Exemplary methylotrophs include Methylobacterium extorquens,Methylobacterium radiotolerans, Methylobacterium Methylobacteriumchloromethanicum, Methylobacterium nodulans, or a combination thereof.

In certain embodiments, methanotrophic bacteria are geneticallyengineered with the capability to convert C₁ substrate feedstock intofatty alcohols. Methanotrophic bacteria have the ability to oxidizemethane as a carbon and energy source. Methanotrophic bacteria areclassified into three groups based on their carbon assimilation pathwaysand internal membrane structure: type I (gamma proteobacteria), type II(alpha proteobacteria, and type X (gamma proteobacteria). Type Imethanotrophs use the ribulose monophosphate (RuMP) pathway for carbonassimilation whereas type II methanotrophs use the serine pathway. TypeX methanotrophs use the RuMP pathway but also express low levels ofenzymes of the serine pathway. Methanotrophic bacteria include obligatemethanotrophs, which can only utilize C1 substrates for carbon andenergy sources, and facultative methanotrophs, which naturally have theability to utilize some multi-carbon substrates as a sole carbon andenergy source.

Exemplary facultative methanotrophs include some species ofMethylocella, Methylocystis, and Methylocapsa (e.g., Methylocellasilvestris, Methylocella palustris, Methylocella tundrae, Methylocystisdaltona strain SB2, Methylocystis bryophila, and Methylocapsa aureaKYG), Methylobacterium organophilum (ATCC 27,886), Methylibiumpetroleiphilum, or high growth variants thereof. Exemplary obligatemethanotrophic bacteria include: Methylococcus capsulatus Bath,Methylomonas 16a (ATCC PTA 2402), Methylosinus trichosporium OB3b (NRRLB-11,196), Methylosinus sporium (NRRL B-11,197), Methylocystis parvus(NRRL B-11,198), Methylomonas methanica (NRRL B-11,199), Methylomonasalbus (NRRL B-11,200), Methylobacter capsulatus (NRRL B-11,201),Methylomonas flagellata sp AJ-3670 (FERM P-2400), Methylacidiphiluminfernorum and Methylomicrobium alcaliphilum, or a high growth variantsthereof.

In still further embodiments, the present disclosure provides C₁metabolizing microorganisms that are syngas metabolizing bacteria, suchas Clostridium, Moorella, Pyrococcus, Eubacterium, Desulfobacterium,Carboxydothermus, Acetogenium, Acetobacterium, Acetoanaerobium,Butyribaceterium, Peptostreptococcus, or a combination thereof.Exemplary methylotrophs include Clostridium autoethanogenum, Clostridiumljungdahli, Clostridium ragsdalei, Clostridium carboxydivorans,Butyribacterium methylotrophicum, Clostridium woodii, Clostridiumneopropanologen, or a combination thereof.

In certain other embodiments, C₁ metabolizing non-photosyntheticmicroorganisms are eukaryotes such as yeast, including Candida,Yarrowia, Hansenula, Pichia, Torulopsis, or Rhodotorula.

In certain other embodiments, the C₁ metabolizing non-photosyntheticmicroorganism is an obligate C₁ metabolizing non-photosyntheticmicroorganism, such as an obligate methanotroph or methylotroph. Infurther embodiments, the C₁ metabolizing non-photosyntheticmicroorganism is a recombinant microorganism comprising a heterologouspolynucleotide encoding a fatty acyl-CoA reductase, a thioesterase,acyl-CoA synthetase, a combination thereof, or all three.

C₁ Metabolizing Microorganisms—Non-Natural or Recombinant

In some embodiments, as described herein, there are provided recombinantC₁ metabolizing microorganisms (e.g., non-natural methanotroph bacteria)may have a fatty acyl-CoA reductase (FAR) that utilize a C₁ substratefeedstock (e.g., methane) to generate C₈ to C₂₄ fatty acid derivatives,such as fatty alcohol. In various embodiments, a recombinant C₁metabolizing microorganism expresses or over expresses a nucleic acidmolecule that encodes a FAR enzyme. In certain embodiments, a FAR enzymemay be endogenous to the C₁ metabolizing microorganism or a FAR enzymemay be heterologous to the C₁ metabolizing microorganism.

In one aspect, the present disclosure provides a non-naturalmethanotroph having a recombinant nucleic acid molecule encoding a fattyacid converting enzyme, wherein the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ fatty aldehyde, fatty alcohol,fatty ester wax, hydroxy fatty acid, dicarboxylic acid, or a combinationthereof. In certain embodiments, the non-natural methanotroph contains afatty acid converting enzyme that is an acyl-CoA dependent fattyacyl-CoA reductase, such as acr1, FAR, CER4 (Genbank Accession No.JN315781.1), or Maqu 2220, capable of forming a fatty alcohol. Incertain embodiments, the non-natural methanotroph contains a fatty acidconverting enzyme that is an acyl-CoA dependent fatty acyl-CoA reductasecapable of forming a fatty aldehyde, such as acr1. In some embodiments,the process will result in the production of fatty alcohols comprisingC₈, C₁₀, C₁₂, C₁₄, C₁₆, C₁₈, C₂₀, C₂₂ or C₂₄ carbons in length.

In any of the aforementioned recombinant C₁ metabolizing microorganismscapable of producing fatty acid derivatives (e.g., fatty alcohols) asencompassed by the present disclosure, the non-natural methanotrophsfurther comprise a recombinant nucleic acid molecule encoding athioesterase, such as a tesA lacking a leader sequence, UcFatB, or BTE.In certain embodiments, the endogenous thioesterase activity is reduced,minimal or abolished as compared to unaltered endogenous thioesteraseactivity.

In any of the aforementioned recombinant C₁ metabolizing microorganismscapable of producing fatty acid derivatives (e.g., fatty alcohols) asencompassed by the present disclosure, the non-natural methanotrophsfurther comprise a recombinant nucleic acid molecule encoding anacyl-CoA synthetase, such as FadD, yng1, or FAA2. In certainembodiments, the endogenous acyl-CoA synthetase activity is reduced,minimal or abolished as compared to unaltered endogenous acyl-CoAsynthetase activity.

In further embodiments, the present disclosure provides a non-naturalmethanotroph having a recombinant nucleic acid molecule encoding aheterologous acyl-CoA dependent fatty acyl-CoA reductase, a recombinantnucleic acid molecule encoding a heterologous thioesterase, and arecombinant nucleic acid molecule encoding a heterologous acyl-CoAsynthetase, wherein the methanotroph is capable of converting a C₁substrate into a C₈-C₂₄ fatty alcohol. In certain embodiments, the fattyacyl-CoA reductase is over-expressed in the non-natural methanotroph ascompared to the expression level of the native fatty acyl-CoA reductase.In certain embodiments, the acyl-CoA dependent fatty acyl-CoA reductasecapable of forming a fatty aldehyde, fatty alcohol, or both is acr1, orthe acyl-CoA independent fatty acyl-CoA reductase capable of forming afatty alcohol is FAR, CER4, or Maqu 2220. In certain embodiments, theacyl-CoA synthetase is FadD, yng1, or FAA2.

In still further embodiments, there is provided a non-naturalmethanotroph having a recombinant nucleic acid molecule encoding aheterologous acyl-CoA independent fatty acyl-CoA reductase, and arecombinant nucleic acid molecule encoding a heterologous thioesterase,wherein the methanotroph is capable of converting a C₁ substrate into aC₈-C₂₄ fatty alcohol. In certain embodiments, the fatty acyl-CoAreductase is over-expressed in the non-natural methanotroph as comparedto the expression level of the native fatty acyl-CoA reductase.

Any of the aforementioned recombinant C₁ metabolizing microorganisms(e.g., non-natural methanotroph bacteria) may have a FAR enzyme orfunctional fragment thereof can be derived or obtained from a species ofMarinobacter, such as M. algicola, M. alkaliphilus, M. aquaeolei, M.arcticus, M. bryozoorum, M. daepoensis, M. excellens, M. flavimaris, M.guadonensis, M. hydrocarbonoclasticus, M. koreenis, M. lipolyticus, M.litoralis, M. lutaoensis, M. maritimus, M. sediminum, M. squalenivirans,M. vinifirmus, or equivalent and synonymous species thereof. In certainembodiments, a FAR enzyme for use in the compositions and methodsdisclosed herein is from marine bacterium Marinobacter algicola DG893(Genbank Accession No. EDM49836.1, FAR “Maa 893”) or Marinobacteraquaeolei VT8 (Genbank Accession No. YP_959486.1, FAR “Maqu_2220”) orOceanobacter sp. RED65 (Genbank Accession No. EAT13695.1, FAR “Ocs_65”).

In still further embodiments of any of the aforementioned recombinant C₁metabolizing microorganisms (e.g., non-natural methanotroph bacteria), aFAR enzyme or functional fragment thereof is FAR_Hch (Hahella chejuensisKCTC 2396, GenBank Accession No. YP_436183.1); FAR_Act (from marineActinobacterium strain PHSC20C1, GenBank Accession No. EAR25464.1),FAR_Mme (marine metagenome, GenBank Accession No. EDD40059.1), FAR_Aec(Acromyrmex echinatior, GenBank Accession No. EGI61731.1), FAR_Cfl(Camponotus floridanus, GenBank Accession No. EFN62239.1), and FAR_Sca(Streptomyces cattleya NRRL 8057, GenBank Accession No. YP_006052652.1).In other embodiments, a FAR enzyme or functional fragment thereof isisolated or derived from Vitis vinifera (FAR_Vvi, GenBank Accession No.CA022305.1 or CAO67776.1), Desulfatibacillum alkenivorans AK-01(FAR_Dal, GenBank Accession No. YP_002430327.1), Simmondsia chinensis(FAR_Sch, GenBank Accession No. AAD38039.1), Bombyx mori (FAR_Bmo,GenBank Accession No. BAC79425.1), Arabidopsis thaliana (FAR_Ath;GenBank Accession No. DQ446732.1 or NM_115529.1), or Ostrinia scapulalis(FAR_Osc; GenBank Accession no. EU817405.1).

In certain embodiments, a FAR_enzyme or functional fragment thereof isderived or obtained from M. algicola DG893 or Marinobacter aquaeolei YT8and has an amino acid sequence that is at least at least 75%, at least80% identical, at least 85% identical, at least 90% identical, at least91% identical, at least 92% identical, at least 93% identical, at least94% identical, at least 95% identical, at least 96% identical, at least97% identical, at least 98% identical, or at least 99% identical to thesequence set forth in Genbank Accession No. EDM49836.1 or YP_959486.1,respectively, or a functional fragment thereof. In another embodiment,the recombinant encoded FAR enzyme has an amino acid sequence that isidentical to the sequence set forth in Genbank Accession No. EDM49836.1or YP_959486.1.

In certain embodiments, recombinant C₁ metabolizing microorganismscapable of producing fatty acid derivatives (e.g., fatty alcohols) asencompassed by the present disclosure will include heterologous nucleicacid molecules encoding a carboxylic acid reductase (CAR). In someembodiments, recombinant microorganisms will additionally comprise oneor more heterologous nucleic acid molecules selected from an acyl-ACPthioesterase (TE), alcohol dehydrogenase (ADH), or phosphopantetheinyltransferase (PPTase), as further described herein.

The present disclosure provides a process for using a recombinant C₁metabolizing microorganism or non-natural methanotroph to convert a C₁substrate (e.g., natural gas, methane) into C₈-C₂₄ fatty alcohols.Microorganisms have evolved efficient processes for the conversion ofcarbon sources to fatty aldehydes, fatty alcohols, fatty ester wax,hydroxy fatty acids, dicarboxylic acids, branched fatty acids, or thelike. The presently disclosed process exploits such efficiency bydiverting the fatty acids so produced to generate derivatives, such aslong chain fatty alcohols, by metabolic engineering of a host C₁metabolizing microorganism. In one aspect, this is accomplished bydeveloping a pathway within a recombinant C₁ metabolizing host cell or anon-natural methanotroph. For example, the enzymes of the pathway mayinclude an acyl-ACP thioesterase (TE), a carboxylic acid reductase(CAR), and a ketoreductase/alcohol dehydrogenase (ADH). In a preferredembodiment, a CAR will be heterologous to the host cell. In someembodiments, a recombinant C₁ metabolizing microorganism or non-naturalmethanotroph will include at least one additional heterologous nucleicacid molecule encoding a polypeptide selected from the set of enzymescomprising acyl-ACP thioesterase (TE), alcoholdehydrogenase/ketoreductase (ADH), or both. In some embodiments, thepathway is engineered in a C₁ metabolizing bacterial host cell, such asa methanotroph host cell.

Carboxylic acid reductases (CARs) are unique ATP- and NADPH-dependentenzymes that reduce carboxylic acids, such as fatty acids to thecorresponding aldehyde. CARs are multi-component enzymes comprising areductase domain; an adenylation domain and a phosphopantetheineattachment site. As disclosed herein, fatty acids, such as those fattyacids comprising 8 to 24 carbon atoms and particularly those fatty acidscomprising 12 carbon atoms (dodecanoic acid) to 18 carbon atoms (stearicacid) may be reduced by a carboxylic acid reductase or variant thereofof this disclosure, such as those having at least 85%, at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100% sequence identity to theCAR of Mycobacterium sp. JLS, Nocardia sp. NRRL5646, or Streptomycesgriseus.

In some embodiments, a variant CAR comprises at least 90% (e.g., atleast 91%, at least 92%, at least 93%, at least 94%, at least 95%, atleast 96%, at least 97%, at least 98%, or at least 99%) sequenceidentity with CAR from Mycobacterium sp. JLS and a substitution of anamino acid at a position corresponding to position 8270, A271, K274,A275, P467, Q584, E626, and/or D701 when aligned with CAR fromMycobacterium sp. JLS. In certain embodiments, a variant CAR may includean amino acid sequence that is at least 85%, (e.g., at least 86%, atleast 87%, at least 88%, at least 89%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98% and at least 99%) identical to CAR fromMycobacterium sp. JLS and an amino acid substitution corresponding toR270W, A271W, K274(G/N/V/I/W/L/M/Q/S), A275F, P467S, Q584R, E626G,D701G, K274L/A369T/L380Y, K274LN358H/E845A, K274M/T282K, K274Q/T282Y,K274S/A715T, K274W/L380G/A477T, K274W/T282E/L380V, K274W/T282Q,K274W/V358R and/or R43c/K274I in CAR from Mycobacterium sp. JLS. Incertain embodiments, a variant CAR will comprise an amino acidsubstitution at position K274 and one or more (e.g., 1, 2 or 3) furtheramino acid substitutions when the variant is aligned with CAR fromMycobacterium sp. JLS. In some embodiments, CAR activity of the variantwill be greater than CAR activity of a reference or parent sequence. CARactivity can be determined, for example, by assays known in the art(see, e.g., U.S. Patent Application Publication No. 2010/0298612).

In some embodiments, a variant CAR may encompass additional amino acidsubstitutions at positions other than those listed herein, including,for example, variants having one or more conservative substitutions. Incertain embodiments, conservatively substituted variants of a CAR willinclude substitutions of a small percentage, such as less than 5%, lessthan 4%, less than 3%, less than 2%, or less than 1% of the amino acidsof a CAR polypeptide sequence.

As noted herein, intracellular expression of a carboxylic acid reductaseof this disclosure will lead to production not only of the fattyaldehyde but also the corresponding fatty alcohol. This is the result ofalcohol dehydrogenase activity within a recombinant host cell. In someembodiments, the process will result in the production of fatty alcoholscomprising C₈, C₁₀, C₁₂, C₁₄, C₁₆, C₁₈, C₂₀, C₂₂ or C₂₄ carbons inlength.

In still further embodiments, there is provided a C₁ metabolizingmicroorganism or non-natural methanotroph having a recombinant nucleicacid molecule encoding a carboxylic acid reductase, a recombinantnucleic acid molecule encoding a phosphopantetheinyl tranferase, and arecombinant nucleic acid molecule encoding an alcohol dehydrogenase,wherein the methanotroph is capable of converting a C₁ substrate into aC₈-C₂₄ fatty alcohol.

In another aspect, this disclosure provides any of the aforementioned C₁metabolizing microorganism or non-natural methanotrophs further comprisea recombinant nucleic acid molecule encoding a P450 enzyme ormonoxygenase enzyme to produce an ω-hydroxy fatty acid. In certainembodiments, the endogenous alcohol dehydrogenase activity is inhibitedas compared to unaltered endogenous alcohol dehydrogenase activity. Inother embodiments, the endogenous alcohol dehydrogenase activity isincreased or elevated as compared to unaltered endogenous alcoholdehydrogenase activity to produce dicarboxylic acid.

In any of the aforementioned non-natural methanotrophs, a fatty alcoholis produced comprising one or more of C₈-C₁₄ or C₁₀-C₁₆ or C₁₂-C₁₄ orC₁₄-C₁₈ or C₁₄-C₂₄ fatty alcohols. In certain embodiments, themethanotroph produces fatty alcohol comprising C₁₀ to C₁₈ fatty alcoholand the C₁₀ to C₁₈ fatty alcohols comprise at least 70% of the totalfatty alcohol. In further embodiments, the methanotroph produces fattyalcohol comprising a branched chain fatty alcohol.

In any of the aforementioned non-natural methanotrophs, the amount offatty aldehyde, fatty alcohol, fatty acid, or dicarboxylic acid producedby the non-natural methanotroph ranges from about 1 mg/L to about 500g/L. In certain other embodiments, a C₁ substrate feedstock for a C₁metabolizing microorganism or non-natural methanotroph as described ismethane, methanol, formaldehyde, formic acid or a salt thereof, carbonmonoxide, carbon dioxide, a methylamine, a methylthiol, a methylhalogen,natural gas, or unconventional natural gas. In certain embodiments, a C₁metabolizing microorganism or non-natural methanotroph is capable ofconverting natural gas, unconventional natural gas or syngas (or syngascomprising methane) into a C₈-C₁₈ fatty aldehyde, fatty alcohol, hydroxyfatty acid, or dicarboxylic acid.

In still further embodiments, there is provided a C₁ metabolizingmicroorganism or non-natural methanotroph having a recombinant nucleicacid molecule encoding a heterologous fatty acyl-CoA reductase, arecombinant nucleic acid molecule encoding a heterologous thioesterase,and a recombinant nucleic acid molecule encoding a heterologous P450 ormonooxygenase, wherein the native alcohol dehydrogenase is inhibited,and wherein the C₁ metabolizing microorganism or methanotroph is capableof converting a C₁ substrate into a C₈-C₂₄ ω-hydroxy fatty acid.

In still further embodiments, there is provided a C₁ metabolizingmicroorganism or non-natural methanotroph having a recombinant nucleicacid molecule encoding a heterologous fatty acyl-CoA reductase, and arecombinant nucleic acid molecule encoding a heterologous thioesterase,wherein the methanotroph is over-expressing native alcohol dehydrogenaseas compared to the normal expression level of native alcoholdehydrogenase, transformed with a recombinant nucleic acid moleculeencoding a heterologous alcohol dehydrogenase, or both, and wherein theC₁ metabolizing microorganism or methanotroph is capable of converting aC₁ substrate into a C₈-C₂₄ dicarboxylic acid alcohol.

In any of the aforementioned C₁ metabolizing microorganisms ornon-natural methanotrophs, the host methanotroph can be Methylococcuscapsulatus Bath strain, Methylomonas 16a (ATCC PTA 2402), Methylosinustrichosporium OB3b (NRRL B-11,196), Methylosinus sporium (NRRLB-11,197), Methylocystis parvus (NRRL B-11,198), Methylomonas methanica(NRRL B-11,199), Methylomonas albus (NRRL B-11,200), Methylobactercapsulatus (NRRL B-11,201), Methylobacterium organophilum (ATCC 27,886),Methylomonas sp AJ-3670 (FERM P-2400), Methylocella silvestris,Methylocella palustris (ATCC 700799), Methylocella tundrae,Methylocystis daltona strain SB2, Methylocystis bryophila, Methylocapsaaurea KYG, Methylacidiphilum infernorum, Methylibium petroleiphilum,Methylomicrobium alcaliphilum, or a combination thereof.

Any of the aforementioned C₁ metabolizing microorganisms or non-naturalmethanotroph bacteria may also have undergone strain adaptation underselective conditions to produce variants with improved properties forfatty acid derivative production, before or after introduction of therecombinant nucleic acid molecules. Improved properties may includeincreased growth rate, yield of desired products (e.g., fatty alcohols),or tolerance to process or culture contaminants. In particularembodiments, a high growth variant C₁ metabolizing microorganism ormethanotroph comprises a host bacteria that is capable of growing on amethane feedstock as a primary carbon and energy source and thatpossesses a faster exponential phase growth rate (i.e., shorter doublingtime) than its parent, reference, or wild-type bacteria (see, e.g., U.S.Pat. No. 6,689,601).

Each of the microorganisms of this disclosure may be grown as anisolated culture, with a heterologous organism that may aid with growth,or one or more of these bacteria may be combined to generate a mixedculture. In still further embodiments, C₁ metabolizingnon-photosynthetic microorganisms of this disclosure are obligate C₁metabolizing non-photosynthetic microorganisms.

C₁ Metabolizing Microorganisms—Producing Fatty Acid Derivatives

In another aspect, as described herein, there are provided methods formaking fatty acid derivatives by culturing a non-natural C₁ metabolizingnon-photosynthetic microorganism with a C₁ substrate feedstock andrecovering the fatty acid derivative, wherein the C₁ metabolizingnon-photosynthetic microorganism comprises a recombinant nucleic acidmolecule encoding a fatty acid converting enzyme, and wherein the C₁metabolizing non-photosynthetic microorganism converts the C₁ substrateinto a C₈-C₂₄ fatty acid derivative comprising a fatty aldehyde, a fattyalcohol, a hydroxy fatty acid, a dicarboxylic acid, or a combinationthereof.

In certain embodiments, the C₁ metabolizing non-photosyntheticmicroorganism being cultured is Methylomonas, Methylobacter,Methylococcus, Methylosinus, Methylocystis, Methylomicrobium,Methanomonas, Methylophilus, Methylobacillus, Methylobacterium,Hyphomicrobium, Xanthobacter, Bacillus, Paracoccus, Nocardia,Arthrobacter, Rhodopseudomonas, Pseudomonas, Candida, Yarrowia,Hansenula, Pichia, Torulopsis, or Rhodotorula. In further embodiments,C₁ metabolizing non-photosynthetic microorganism being cultured isbacteria, such as a methanotroph or methylotroph.

The methanotroph may be a Methylomonas sp. 16a (ATCC PTA 2402),Methylosinus trichosporium (NRRL B-11,196), Methylosinus sporium (NRRLB-11,197), Methylocystis parvus (NRRL B-11,198), Methylomonas methanica(NRRL B-11,199), Methylomonas albus (NRRL B-11,200), Methylobactercapsulatus (NRRL B-11,201), Methylobacterium organophilum (ATCC 27,886),Methylomonas sp. AJ-3670 (FERM P-2400), Methylocella silvestris,Methylacidiphilum infernorum, Methylibium petroleiphilum, or acombination thereof. In certain embodiments, the methanotroph culturefurther comprises one or more heterologous bacteria.

The methylotroph may be a Methylobacterium extorquens, Methylobacteriumradiotolerans, Methylobacterium populi, Methylobacteriumchloromethanicum, Methylobacterium nodulans, or a combination thereof.

In further embodiments, the C₁ metabolizing microorganism or bacteriacan metabolize natural gas, unconventional natural gas, or syngas. Incertain embodiments, the syngas metabolizing bacteria includeClostridium autoethanogenum, Clostridium ljungdahli, Clostridiumragsdalei, Clostridium carboxydivorans, Butyribacteriummethylotrophicum, Clostridium woodii, Clostridium neopropanologen, or acombination thereof. In certain other embodiments, the metabolizingnon-photosynthetic microorganism is an obligate C₁ metabolizingnon-photosynthetic microorganism. In certain other embodiments, themetabolizing non-photosynthetic microorganism is an facultative C₁metabolizing non-photosynthetic microorganism.

In any of the aforementioned methods, the cultured C₁ metabolizingmicroorganism contains a fatty acid converting enzyme that is anacyl-CoA dependent fatty acyl-CoA reductase, such as acr1, FAR, CER4(Genbank Accession No. JN315781.1), or Maqu_2220, capable of forming afatty alcohol. In certain embodiments, the C₁ metabolizing microorganismbeing cultured contains a fatty acid converting enzyme that is anacyl-CoA dependent fatty acyl-CoA reductase capable of forming a fattyaldehyde, such as acr1. In some embodiments, the process will result inthe production of fatty alcohols comprising C₈, C₁₀, C₁₂, C₁₄, C₁₆, C₁₈,C₂₀, C₂₂ or C₂₄ carbons in length.

In any of the aforementioned recombinant C₁ metabolizing microorganismscapable of producing fatty acid derivatives (e.g., fatty alcohols) asencompassed by the present methods, the C₁ metabolizing microorganismsfurther comprise a recombinant nucleic acid molecule encoding athioesterase, such as a tesA lacking a leader sequence, UcFatB, or BTE.In certain embodiments, the endogenous thioesterase activity is reduced,minimal or abolished as compared to unaltered endogenous thioesteraseactivity.

In any of the aforementioned recombinant C₁ metabolizing microorganismscapable of producing fatty acid derivatives (e.g., fatty alcohols) asencompassed by the present methods, the C₁ metabolizing microorganismsfurther comprise a recombinant nucleic acid molecule encoding anacyl-CoA synthetase, such as FadD, yng1, or FAA2. In certainembodiments, the endogenous acyl-CoA synthetase activity is reduced,minimal or abolished as compared to unaltered endogenous acyl-CoAsynthetase activity.

In further embodiments, the present methods provide a C₁ metabolizingmicroorganism having a recombinant nucleic acid molecule encoding aheterologous acyl-CoA dependent fatty acyl-CoA reductase, a recombinantnucleic acid molecule encoding a heterologous thioesterase, and arecombinant nucleic acid molecule encoding a heterologous acyl-CoAsynthetase, wherein the C₁ metabolizing microorganism is capable ofconverting a C₁ substrate into a C₈-C₂₄ fatty alcohol. In certainembodiments, the fatty acyl-CoA reductase is over-expressed in thecultured C₁ metabolizing microorganism as compared to the expressionlevel of the native fatty acyl-CoA reductase. In certain embodiments,the acyl-CoA dependent fatty acyl-CoA reductase capable of forming afatty aldehyde, fatty alcohol, or both is acr1, or the acyl-CoAindependent fatty acyl-CoA reductase capable of forming a fatty alcoholis FAR, CER4, or Maqu_2220. In certain embodiments, the acyl-CoAsynthetase is FadD, yng1, or FAA2.

In still further embodiments, the methods provide a C₁ metabolizingmicroorganism having a recombinant nucleic acid molecule encoding aheterologous acyl-CoA independent fatty acyl-CoA reductase, and arecombinant nucleic acid molecule encoding a heterologous thioesterase,wherein the methanotroph converts a C₁ substrate into a C₈-C₂₄ fattyalcohol. In certain embodiments, the fatty acyl-CoA reductase isover-expressed in the C₁ metabolizing microorganism as compared to theexpression level of the native fatty acyl-CoA reductase.

In still further embodiments, the methods provide a cultured C₁metabolizing microorganism having a recombinant nucleic acid moleculeencoding a carboxylic acid reductase, a recombinant nucleic acidmolecule encoding a phosphopantetheinyl tranferase, and a recombinantnucleic acid molecule encoding an alcohol dehydrogenase, wherein themethanotroph is capable of converting a C₁ substrate into a C₈-C₂₄ fattyalcohol.

In another aspect, the methods of this disclosure provide any of theaforementioned cultured C₁ metabolizing microorganisms furthercomprising a recombinant nucleic acid molecule encoding a P450 enzyme ormonoxygenase enzyme to produce ω-hydroxy fatty acid. In certainembodiments, the endogenous alcohol dehydrogenase activity is inhibitedas compared to unaltered endogenous alcohol dehydrogenase activity. Inother embodiments, the endogenous alcohol dehydrogenase activity isincreased or elevated as compared to unaltered endogenous alcoholdehydrogenase activity to produce dicarboxylic acid.

In any of the aforementioned cultured C₁ metabolizing microorganisms,the methods produce a fatty alcohol comprising one or more of C₈-C₁₄ orC₁₀-C₁₆ or C₁₂-C₁₄ or C₁₄-C₁₅ or C₁₄-C₂₄ fatty alcohols. In certainembodiments, the C₁ metabolizing microorganisms produce fatty alcoholcomprising C₁₀ to C₁₈ fatty alcohol and the C₁₀ to C₁₈ fatty alcoholscomprise at least 70% of the total fatty alcohol. In furtherembodiments, the C₁ metabolizing microorganisms produce fatty alcoholcomprising a branched chain fatty alcohol.

In any of the aforementioned cultured C₁ metabolizing microorganism, theamount of fatty aldehyde, fatty alcohol, fatty acid, or dicarboxylicacid produced by the C₁ metabolizing microorganisms range from about 1mg/L to about 500 g/L. In certain other embodiments, the C₁ substratefeedstock for the C₁ metabolizing microorganisms used in the methods ofmaking fatty acid derivatives is methane, methanol, formaldehyde, formicacid or a salt thereof, carbon monoxide, carbon dioxide, a methylamine,a methylthiol, a methylhalogen, natural gas, or unconventional naturalgas. In certain embodiments, the C₁ metabolizing microorganisms convertnatural gas, unconventional natural gas or syngas comprising methaneinto a C₈-C₁₈ fatty aldehyde, fatty alcohol, hydroxy fatty acid, ordicarboxylic acid.

In still further embodiments, the methods provide a C₁ metabolizingmicroorganism having a recombinant nucleic acid molecule encoding aheterologous fatty acyl-CoA reductase, a recombinant nucleic acidmolecule encoding a heterologous thioesterase, and a recombinant nucleicacid molecule encoding a heterologous P450 or monooxygenase, wherein thenative alcohol dehydrogenase is inhibited, and wherein the C₁metabolizing microorganism converts a C₁ substrate into a C₈-C₂₄ω-hydroxy fatty acid.

In still further embodiments, the methods provide a C₁ metabolizingmicroorganism having a recombinant nucleic acid molecule encoding aheterologous fatty acyl-CoA reductase, and a recombinant nucleic acidmolecule encoding a heterologous thioesterase, wherein the C₁metabolizing microorganism over-expresses native alcohol dehydrogenaseas compared to the normal expression level of native alcoholdehydrogenase, is transformed with a recombinant nucleic acid moleculeencoding a heterologous alcohol dehydrogenase, or both, wherein the C₁metabolizing microorganism is capable of converting a C₁ substrate intoa C₈-C₂₄ dicarboxylic acid alcohol.

In any of the aforementioned methods, the C₁ metabolizing microorganismscan be cultured in a controlled culturing unit, such as a fermentor orbioreactor.

Codon Optimization

Expression of recombinant proteins is often difficult outside theiroriginal host. For example, variation in codon usage bias has beenobserved across different species of bacteria (Sharp et al., Nucl.Acids. Res. 33:1141, 2005). Over-expression of recombinant proteins evenwithin their native host may also be difficult. In certain embodimentsof the invention, nucleic acids (e.g., nucleic acids encoding fattyalcohol forming enzymes) that are to be introduced into hostmethanotrophic bacteria as described herein may undergo codonoptimization to enhance protein expression. Codon optimization refers toalteration of codons in genes or coding regions of nucleic acids fortransformation of a methanotrophic bacterium to reflect the typicalcodon usage of the host bacteria species without altering thepolypeptide for which the DNA encodes. Codon optimization methods foroptimum gene expression in heterologous hosts have been previouslydescribed (see, e.g., Welch et al., PLoS One 4:e7002, 2009; Gustafssonet al., Trends Biotechnol. 22:346, 2004; Wu et al., Nucl. Acids Res.35:D76, 2007; Villalobos et al., BMC Bioinformatics 7:285, 2006; U.S.Patent Application Publication Nos. US 2011/0111413; US 2008/0292918;disclosure of which are incorporated herein by reference, in theirentirety).

Transformation Methods

Any of the recombinant C₁ metabolizing microorganisms or methanotrophicbacteria described herein may be transformed to comprise at least oneexogenous nucleic acid to provide the host bacterium with a new orenhanced activity (e.g., enzymatic activity) or may be geneticallymodified to remove or substantially reduce an endogenous gene functionusing a variety of methods known in the art.

Transformation refers to the transfer of a nucleic acid (e.g., exogenousnucleic acid) into the genome of a host cell, resulting in geneticallystable inheritance. Host cells containing the transformed nucleic acidmolecules are referred to as “non-naturally occurring” or “recombinant”or “transformed” or “transgenic” cells.

Expression systems and expression vectors useful for the expression ofheterologous nucleic acids in C₁ metabolizing microorganisms ormethanotrophic bacteria are known.

Electroporation of C₁ metabolizing bacteria has been previouslydescribed in Toyama et al., FEMS Microbiol. Lett. 166:1, 1998; Kim andWood, Appl. Microbiol. Biotechnol. 48:105, 1997; Yoshida et al.,Biotechnol. Lett. 23:787, 2001, and U.S. Patent Application PublicationNo. US 2008/0026005.

Bacterial conjugation, which refers to a particular type oftransformation involving direct contact of donor and recipient cells, ismore frequently used for the transfer of nucleic acids into C₁metabolizing bacteria. Bacterial conjugation involves mixing “donor” and“recipient” cells together in close contact with each other. Conjugationoccurs by formation of cytoplasmic connections between donor andrecipient bacteria, with unidirectional transfer of newly synthesizeddonor nucleic acid molecules into the recipient cells. A recipient in aconjugation reaction is any cell that can accept nucleic acids throughhorizontal transfer from a donor bacterium. A donor in a conjugationreaction is a bacterium that contains a conjugative plasmid, conjugativetransposon, or mobilized plasmid. The physical transfer of the donorplasmid can occur through a self-transmissible plasmid or with theassistance of a “helper” plasmid. Conjugations involving C₁ metabolizingbacteria have been previously described in Stolyar et al.,Mikrobiologiya 64:686, 1995; Motoyama et al., Appl. Micro. Biotech.42:67, 1994; Lloyd et al., Arch. Microbiol. 171:364, 1999; and Odom etal., PCT Publication No. WO 02/18617; Ali et al., Microbiol. 152:2931,2006.

Expression of heterologous nucleic acids in C1 metabolizing bacteria isknown in the art (see, e.g., U.S. Pat. No. 6,818,424; U.S. PatentApplication Publication No. US 2003/0003528). Mu transposon basedtransformation of methylotrophic bacteria has been described (Akhverdyanet al., Appl. Microbiol. Biotechnol. 91:857, 2011). A mini-Tn7transposon system for single and multicopy expression of heterologousgenes without insertional inactivation of host genes in Methylobacteriumhas been described (U.S. Patent Application Publication No. US2008/0026005).

Various methods for inactivating, knocking-out, or deleting endogenousgene function in C₁ metabolizing bacteria may be used. Allelic exchangeusing suicide vectors to construct deletion/insertional mutants in slowgrowing C₁ metabolizing bacteria have also been described in Toyama andLidstrom, Microbiol. 144:183, 1998; Stolyar et al., Microbiol. 145:1235,1999; Ali et al., Microbiol. 152:2931, 2006; Van Dien et al., Microbiol.149:601, 2003.

Suitable homologous or heterologous promoters for high expression ofexogenous nucleic acids may be utilized. For example, U.S. Pat. No.7,098,005 describes the use of promoters that are highly expressed inthe presence of methane or methanol for heterologous gene expression inC₁ metabolizing bacteria. Additional promoters that may be used includedeoxy-xylulose phosphate synthase methanol dehydrogenase operon promoter(Springer et al., FEMS Microbiol. Lett. 160:119, 1998); the promoter forPHA synthesis (Foellner et al., Appl. Microbiol. Biotechnol. 40:284,1993); or promoters identified from a native plasmid in methylotrophs(European Patent No. EP 296484). Non-native promoters include the lacoperon Plac promoter (Toyama et al., Microbiol. 143:595, 1997) or ahybrid promoter such as Ptrc (Brosius et al., Gene 27:161, 1984). Incertain embodiments, promoters or codon optimization are used for highconstitutive expression of exogenous nucleic acids encoding glycerolutilization pathway enzymes in host methanotrophic bacteria. Regulatedexpression of an exogenous nucleic acid in the host methanotrophicbacterium may also be utilized. In particular, regulated expression ofexogenous nucleic acids encoding glycerol utilization enzymes may bedesirable to optimize growth rate of the non-naturally occurringmethanotrophic bacteria. It is possible that in the absence of glycerol(e.g., during growth on methane as a carbon source), for the glycerolutilization pathway to run in reverse, resulting in secretion ofglycerol from the bacteria, thereby lowering growth rate. Controlledexpression of nucleic acids encoding glycerol utilization pathwayenzymes in response to the presence of glycerol may optimize bacterialgrowth in a variety of carbon source conditions. For example, aninducible/regulatable system of recombinant protein expression inmethylotrophic and methanotrophic bacteria, as described in U.S. PatentApplication Publication No. US 2010/0221813, may be used. Regulation ofglycerol utilization genes in bacteria is well established (Schweizerand Po, J. Bacteriol. 178:5215, 1996; Abram et al., Appl. Environ.Microbiol. 74:594, 2008; Darbon et al., Mol. Microbiol. 43:1039, 2002;Weissenborn et al., J. Biol. Chem. 267:6122, 1992). Glycerol utilizationregulatory elements may also be introduced or inactivated in hostmethanotrophic bacteria for desired expression levels of exogenousnucleic acid molecules encoding glycerol utilization pathway enzymes.

Methods of screening are disclosed in Brock, supra. Selection methodsfor identifying allelic exchange mutants are known in the art (see,e.g., U.S. Patent Appl. Publication No. US 2006/0057726, Stolyar et al.,Microbiol. 145:1235, 1999; and Ali et al., Microbiol. 152:2931, 2006.

Culture Methods

A variety of culture methodologies may be used for recombinantmethanotrophic bacteria described herein. For example, methanotrophicbacteria may be grown by batch culture or continuous culturemethodologies. In certain embodiments, the cultures are grown in acontrolled culture unit, such as a fermentor, bioreactor, hollow fibermembrane bioreactor, or the like.

A classical batch culturing method is a closed system where thecomposition of the media is set at the beginning of the culture and notsubject to external alterations during the culture process. Thus, at thebeginning of the culturing process, the media is inoculated with thedesired C₁ metabolizing microorganism (e.g., methanotroph) and growth ormetabolic activity is permitted to occur without adding anything to thesystem. Typically, however, a “batch” culture is batch with respect tothe addition of carbon source and attempts are often made at controllingfactors such as pH and oxygen concentration. In batch systems, themetabolite and biomass compositions of the system change constantly upto the time the culture is terminated. Within batch cultures, cellsmoderate through a static lag phase to a high growth logarithmic phaseand finally to a stationary phase where growth rate is diminished orhalted. If untreated, cells in the stationary phase will eventually die.Cells in logarithmic growth phase are often responsible for the bulkproduction of end product or intermediate in some systems. Stationary orpost-exponential phase production can be obtained in other systems.

The Fed-Batch system is a variation on the standard batch system.Fed-Batch culture processes comprise a typical batch system with themodification that the substrate is added in increments as the cultureprogresses. Fed-Batch systems are useful when catabolite repression isapt to inhibit the metabolism of the cells and where it is desirable tohave limited amounts of substrate in the media. Measurement of theactual substrate concentration in Fed-Batch systems is difficult and istherefore estimated on the basis of the changes of measurable factors,such as pH, dissolved oxygen, and the partial pressure of waste gasessuch as CO₂. Batch and Fed-Batch culturing methods are common and knownin the art (see, e.g., Thomas D. Brock, Biotechnology: A Textbook ofIndustrial Microbiology, 2^(nd) Ed. (1989) Sinauer Associates, Inc.,Sunderland, Mass.; Deshpande, Appl. Biochem. Biotechnol. 36:227, 1992).

Continuous cultures are “open” systems where a defined culture media isadded continuously to a bioreactor and an equal amount of conditionedmedia is removed simultaneously for processing. Continuous culturesgenerally maintain the cells at a constant high liquid phase densitywhere cells are primarily in logarithmic phase growth. Alternatively,continuous culture may be practiced with immobilized cells where carbonand nutrients are continuously added and valuable products, by-products,and waste products are continuously removed from the cell mass. Cellimmobilization may be performed using a wide range of solid supportscomposed of natural and/or synthetic materials.

Continuous or semi-continuous culture allows for the modulation of onefactor or any number of factors that affect cell growth or end productconcentration. For example, one method will maintain a limited nutrient,such as the carbon source or nitrogen level, at a fixed rate and allowall other parameters to modulate. In other systems, a number of factorsaffecting growth can be altered continuously while the cellconcentration, measured by media turbidity, is kept constant. Continuoussystems strive to maintain steady state growth conditions and thus thecell loss due to media being drawn off must be balanced against the cellgrowth rate in the culture. Methods of modulating nutrients and growthfactors for continuous culture processes, as well as techniques formaximizing the rate of product formation, are well known in the art, anda variety of methods are detailed by Brock, supra.

Fatty Acid Derivative Compositions

By way of background, stable isotopic measurements and mass balanceapproaches are widely used to evaluate global sources and sinks ofmethane (see Whiticar and Faber, Org. Geochem. 10:759, 1986; Whiticar,Org. Geochem. 16: 531, 1990). To use δ¹³C values of residual methane todetermine the amount oxidized, it is necessary to know the degree ofisotopic fractionation caused by microbial oxidation of methane. Forexample, aerobic methanotrophs can metabolize methane through a specificenzyme, methane monoxygenase (MMO). Methanotrophs convert methane tomethanol and subsequently formaldehyde. Formaldehyde can be furtheroxidized to CO₂ to provide energy to the cell in the form of reducingequivalents (NADH), or incorporated into biomass through either the RuMPor Serine cycles (Hanson and Hanson, Microbiol. Rev. 60:439, 1996),which are directly analogous to carbon assimilation pathways inphotosynthetic organisms.

More specifically, a Type I methanotroph uses the RuMP pathway forbiomass synthesis and generates biomass entirely from CH₄, whereas aType II methanotroph uses the serine pathway that assimilates 50-70% ofthe cell carbon from CH₄ and 30-50% from CO₂ (Hanson and Hanson, 1996).Methods for measuring carbon isotope compositions are provided in, forexample, Templeton et al. (Geochim. Cosmochim. Acta 70:1739, 2006),which methods are hereby incorporated by reference in their entirety.The ¹³C/¹²C stable carbon ratio of an oil composition from a biomass(provided as a “delta” value ‰, δ¹³C) can vary depending on the sourceand purity of the C₁ substrate used (see, e.g., FIG. 7).

Fatty acid derivative compositions produced using a C₁ metabolizingnon-photosynthetic microorganisms and methods described herein, may bedistinguished from fatty acids produced from petrochemicals or fromphotosynthetic microorganisms or plants by carbon fingerprinting. Incertain embodiments, compositions of C₈ to C₂₄ fatty aldehyde, fattyalcohol, fatty ester wax, hydroxy fatty acid, dicarboxylic acid, or anycombination thereof have a δ¹³C of less than −30‰, less than −31‰, lessthan −32‰, less than −33‰, less than −34‰, less than −35‰, less than−36‰, less than −37‰, less than −38‰, less than −39‰, less than −40‰,less than −41‰, less than −42‰, less than −43‰, less than −44‰, lessthan −45‰, less than −46‰, less than −47‰, less than −48‰, less than−49‰, less than −50‰, less than −51‰, less than −52‰, less than −53‰,less than −54‰, less than −55‰, less than −56‰, less than −57‰, lessthan −58‰, less than −59‰, less than −60‰, less than −61‰, less than−62‰, less than −63‰, less than −64‰, less than −65‰, less than −66‰,less than −67‰, less than −68‰, less than −69‰, or less than −70‰.

In some embodiments, a C₁ metabolizing microorganism biomass comprises afatty acid derivative composition as described herein, wherein the fattyacid derivative containing biomass or a fatty acid derivativecomposition has a δ¹³C of about −35‰ to about −50‰, −45‰ to about −35‰,or about −50‰ to about −40‰, or about −45‰ to about −65‰, or about −60‰to about −70‰, or about −30‰ to about −70‰. In certain embodiments, afatty acid derivative composition comprises at least 50% fatty acids orcomprises at least 50% fatty acid derivatives. In further embodiments, afatty acid derivative composition comprises fatty aldehyde, fattyalcohol, fatty ester wax, hydroxy fatty acid, dicarboxylic acid, or anycombination thereof. In still further embodiments, a fatty acidderivative composition comprises C₈-C₂₄ fatty alcohol, C₈-C₂₄ branchedchain fatty alcohol, C₈-C₂₄ fatty aldehyde, C₈-C₂₄ ω-hydroxy fatty acid,or C₈-C₂₄ dicarboxylic acid alcohol. In yet further embodiments, a fattyacid derivative composition comprises a majority (more than 50% w/w) offatty acids having carbon chain lengths ranging from C₈ to C₁₄ or fromC₁₀ to C₁₆ or from C₁₄ to C₂₄, or a majority of fatty acid derivativeshaving carbon chain lengths of less than C₁₈, or a fatty alcoholcontaining composition wherein at least 70% of the total fatty alcoholcomprises C₁₀ to C₁₈ fatty alcohol.

In further embodiments, a C₁ metabolizing non-photosyntheticmicroorganism fatty acid derivative containing biomass or a fatty acidderivative composition has a δ¹³C of less than about −30‰, or rangesfrom about −40‰ to about −60‰. In certain embodiments, the fatty acidderivative containing biomass comprises a recombinant C₁ metabolizingnon-photosynthetic microorganism together with the spent media, or thefatty acid derivative containing biomass comprises a spent mediasupernatant composition from a culture of a recombinant C₁ metabolizingnon-photosynthetic microorganism, wherein the δ¹³C of the fatty acidderivative containing biomass or a fatty acid derivative compositionobtained therefrom is less than about −30‰. In certain otherembodiments, a fatty acid derivative composition is isolated, extractedor concentrated from a fatty acid derivative containing biomass, whichcan comprise recombinant C₁ metabolizing non-photosyntheticmicroorganisms together with the spent media from a culture, or a spentmedia supernatant composition from a culture of a recombinant C₁metabolizing non-photosynthetic microorganism.

In certain embodiments, fatty acid derivative containing biomass or afatty acid derivative composition is of a recombinant C₁ metabolizingnon-photosynthetic microorganism comprises a heterologous polynucleotideencoding a fatty acid converting enzyme. In further embodiments, such aheterologous polynucleotide encodes a fatty acyl-CoA reductase,carboxylic acid reductase, thioesterase, acyl-CoA synthetase, P450,monoxygenase, or any combination thereof. In further embodiments, fattyacid derivative containing biomass or a fatty acid derivativecomposition is of a recombinant C₁ metabolizing non-photosyntheticmicroorganism comprising a heterologous nucleic acid sequence asdescribed herein that is codon optimized for efficient expression in aC₁ metabolizing non-photosynthetic microorganism.

Exemplary organisms for use in generating fatty acid derivativecontaining biomass or a fatty acid derivative composition is of arecombinant C₁ metabolizing non-photosynthetic microorganisms of thisdisclosure include bacteria or yeast. In certain embodiments, fatty acidderivative containing biomass or a fatty acid derivative composition isof a C₁ metabolizing bacteria from a methanotroph or methylotroph, suchas a Methylomonas sp. 16a (ATCC PTA 2402), Methylosinus trichosporiumOB3b (NRRL B-11,196), Methylosinus sporium (NRRL B-11,197),Methylocystis parvus (NRRL B-11,198), Methylomonas methanica (NRRLB-11,199), Methylomonas albus (NRRL B-11,200), Methylobacter capsulatusY (NRRL B-11,201), Methylococcus capsulatus Bath (NCIMB 11132),Methylobacterium organophilum (ATCC 27,886), Methylomonas sp. AJ-3670(FERM P-2400), Methylomicrobium alcaliphilum, Methylocella silvestris,Methylacidiphilum infernorum, Methylibium petrolelphilum,Methylobacterium extorquens, Methylobacterium radiotolerans,Methylobacterium populi, Methylobacterium chloromethanicum,Methylobacterium nodulans, or any combination thereof.

In further embodiments, a fatty acid derivative containing biomass or afatty acid derivative composition is of a C₁ metabolizing bacteria froma recombinant C₁ metabolizing bacteria of this disclosure is a syngasmetabolizing bacteria, such as Clostridium autoethanogenum, Clostridiumljungdahli, Clostridium ragsdalei, Clostridium carboxydivorans,Butyribacterium methylotrophicum, Clostridium woodii, Clostridiumneopropanologen, or a combination thereof.

EXAMPLES Example 1 Lipid Extraction from C₁ Metabolizing Microorganisms

A fatty acid oil composition contained within a harvested bacterialbiomass was extracted using a modified version of Folch's extractionprotocol (Folch et al., J. Biol. Chem. 226:497, 1957), performed at 20°C. (i.e., room temperature) and in an extraction solution made up of onevolume methanol in two volumes chloroform (CM solution). About 5 g wetcell weight (WCW) of either fresh bacterial biomass (or bacterialbiomass stored at −80° C. and subsequently thawed) was used forextractions. A 100 mL CM solution was added to the cell material and themixture was extracted vigorously in a separatory funnel. After at least10 minutes, three phases were resolved. The organic phase containingextracted lipids settled at the bottom of the separatory funnel, whichwas drained into a clean glass bottle. The middle layer containedprimarily lysed cellular materials and could be separated from the lightwater phase containing salts and other soluble cellular components.

Optionally, solids in the water phase can be concentrated using acentrifuge or other mechanical concentration equipment. The waterremoved from the solids may be recycled, while the solids, with someresidual water, can be fed to a solids processing unit.

To enhance the lipid extraction efficiency, a second extraction step wascarried out by adding an additional 100 mL fresh CM solution directlyinto the separatory funnel containing the remaining lysed cell mass andresidual water. The mixture was again mixed thoroughly, the phasesallowed to separate, and the bottom organic phases from the twoextractions were pooled. The pooled organic phases were then washed with100 mL deionized water in a separatory funnel to remove any residualwater-soluble material. The separated organic fraction was againisolated from the bottom of the separatory funnel and solvent wasremoved by rotary evaporation with heat, preferably in the absence ofoxygen, or by evaporation at 55° C. under a stream of nitrogen.

TABLE 1 Extracted Lipid Content from Three Different Methanotrophs LipidFraction Batch No. Reference Strain (g/g DCW)* 68C Methylosinustrichosporium OB3b 40.1 62A Methylococcus capsulatus Bath 10.3 66AMethylomonas sp. 16a 9.3 *Grams of extracted material per gram of drycell weight (DCW)

The solidified fatty acid compositions extracted from the harvestedcultures of M. trichosporium OB3b, Methylococcus capsulatus Bath, andMethylomonas sp. 16a were each weighed and are shown as the weightfraction of the original dry cell weight (DCW) in Table 1. These datashow that a significant fraction of the DCW from these C₁ metabolizingmicroorganisms is made up of lipids.

The fatty acid composition from Methylomonas sp. 16a biomass was alsoextracted using hexane:isopropanol (HIP) extraction method of Hara andRadin (Anal. Biochem. 90:420, 1978). Analysis of the fatty acidcomposition extracted using the HIP method showed that the fatty acidcomposition was essentially identical to the fatty acid compositionextracted using the modified Folch method (data not shown).

Example 2 Fatty Acid Methyl Ester Conversion of Lipids from C₁Metabolizing Microorganisms

The lipid fractions extracted from M. capsulatus Bath, M. trichosporiumOB3b, and Methylomonas sp. 16a culture biomass in the form of dry solidswere individually hydrolyzed with potassium hydroxide (KOH) andconverted into fatty acid methyl esters (FAMEs) via reaction withmethanol in a single step. About 5 g of extracted solid lipids in a 10mL glass bottle were dissolved with 5 mL of 0.2 M. KOH solution oftoluene:methanol (1:1 v/v). The bottle was agitated vigorously and thenmixed at 250 rpm at 42° C. for 60 minutes, after which the solution wasallowed to cool to ambient temperature and transferred to a separatoryfunnel. Approximately 5 mL distilled water and 5 mL CM solution wereadded to the separatory funnel, mixed, and then the phases were allowedto separate by gravity or by centrifugation (3,000 rpm, 25° C.) for 5minutes. The top aqueous layer was removed, which contains dissolvedglycerol phosphate esters, while the heavy oil phase (bottom) wascollected and concentrated to dryness by rotary evaporation or by aconstant nitrogen stream.

Analysis of FFAs and FAMEs found in lipids from each methanotrophculture was performed using a gas chromatograph/mass spectrometer(GC/MS). The solids collected before and after thehydrolysis/transesterification step were dissolved in 300 μL butylacetate containing undecanoic acid as an internal standard for GC/MSanalysis. The resulting solution was centrifuged for 5 minutes at 14,000rpm to remove insoluble residues. The same volume equivalent ofN,O-Bis(trimethylsilyl)trifluoroacetamide was added to the supernatantfrom the centrifugation step and vortexed briefly. Samples were loadedon an GC equipped with mass spectrometer detector (HP 5792), and anAgilent HP-5 MS GC/MS column (30.0 m×250 μm×0.25 μm film thickness) wasused to separate the FFAs and FAMEs. Identity of FFAs and FAMEs wasconfirmed with retention time and electron ionization of mass spectra oftheir standards. The GC/MS method utilized helium as the carrier gas ata flow of 1.2 mL/min. The injection port was held at 250° C. with asplit ratio of 20:1. The oven temperature was held at 60° C. for 1minute followed by a temperature gradient comprising an 8° C.increase/min until 300° C. The % area of each FFA and FAME wascalculated based on total ions from the mass detector response.

The solid residue collected before and afterhydrolysis/transesterification were analyzed for FFAs and FAMEs by GC/MS(see Table 2).

TABLE 2 Relative composition of FFA and FAME in Extracted Lipids Beforeand After KOH Hydrolysis/Esterification M. capsulatus M. trichosporiumMethylomonas Bath OB3b sp. 16a With With With Fatty hy- Without hy-Without hy- Without Acid drolysis hydrolysis drolysis hydrolysisdrolysis hydrolysis Type % Area % Area % Area C14:0 — — — — — 12.9 FFAC16:0 0.5 84.1 — 43.7 — 8.1 FFA C16:1 — 13.4 — — — 76.1 FFA C18:0 0.4 2.5 — 31.2 — 1.3 FFA C18:1 — — — 25.1 — 1.5 FFA C14:0 3.4 — — —  7.2 —FAME C16:0 54.4  — 1.4 — 14.7 — FAME C16:1 41.3  — 6.8 — 61.3 — FAMEC18:0 — — 1.0 — N.D. — FAME C18:1 — — 90.8  — 16.8 — FAME *—= Notdetectable; % Area: MS detector response-Total ions

As is evident from Table 2, extracted lipid compositions beforehydrolysis/transesterification have abundant free fatty acids andadditional fatty acids present, but the FFAs are converted into fattyacid methyl esters of various lengths afterhydrolysis/transesterification. These data indicate that oilcompositions from the C₁ metabolizing microorganisms of this disclosurecan be refined and used to make high-value molecules.

Example 3 Stable Carbon Isotope Distribution in Lipids from C₁Metabolizing Microorganisms

Dry samples of M. trichosporium biomass and lipid fractions wereanalyzed for carbon and nitrogen content (% dry weight), and carbon(¹³C) and nitrogen (¹⁵N) stable isotope ratios via elementalanalyzer/continuous flow isotope ratio mass spectrometry using a CHNOSElemental Analyzer (vario ISOTOPE cube, Elementar, Hanau, Germany)coupled with an IsoPrime100 IRMS (Isoprime, Cheadle, UK). Samples ofmethanotrophic biomass cultured in fermenters or serum bottles werecentrifuged, resuspended in deionized water and volumes corresponding to0.2-2 mg carbon (about 0.5-5 mg dry cell weight) were transferred to 5×9mm tin capsules (Costech Analytical Technologies, Inc., Valencia,Calif.) and dried at 80° C. for 24 hours. Similarly, previouslyextracted lipid fractions were suspended in chloroform and volumescontaining 0.1-1.5 mg carbon were transferred to tin capsules andevaporated to dryness at 80° C. for 24 hours. Standards containing 0.1mg carbon provided reliable δ¹³C values.

The isotope ratio is expressed in “delta” notation (‰), wherein theisotopic composition of a material relative to that of a standard on aper million deviation basis is given by δ¹³C (orδ¹⁵N)=(R_(sample)/R_(Standard-1))×1,000, wherein R is the molecularratio of heavy to light isotope forms. The standard for carbon is theVienna Pee Dee Belemnite (V-PDB) and for nitrogen is air. The NIST(National Institute of Standards and Technology) proposed SRM (StandardReference Material) No. 1547, peach leaves, was used as a calibrationstandard. All isotope analyses were conducted at the Center for StableIsotope Biogeochemistry at the University of California, Berkeley.Long-term external precision for C and N isotope analyses is 0.10‰ and0.15‰, respectively. M. trichosporium strain OB3b was grown on methanein three different fermentation batches, M. capsulatus Bath was grown onmethane in two different fermentation batches, and Methylomonas sp. 16awas grown on methane in a single fermentation batch. The biomass fromeach of these cultures was analyzed for stable carbon isotopedistribution (δ¹³C values; see Table 3).

TABLE 3 Stable Carbon Isotope Distribution in Different MethanotrophsMethanotroph Batch No. EFT (h)† OD₆₀₀ DCW* δ¹³C Cells Mt OB3b 68A 481.80 1.00 −57.9 64 1.97 1.10 −57.8 71 2.10 1.17 −58.0 88 3.10 1.73 −58.197 4.30 2.40 −57.8 113 6.00 3.35 −57.0 127 8.40 4.69 −56.3 Mt OB3b 68B32 2.90 1.62 −58.3 41 4.60 2.57 −58.4 47 5.89 3.29 −58.0 56 7.90 4.41−57.5 Mt OB3b 68C 72 5.32 2.97 −57.9 79.5 5.90 3.29 −58.0 88 5.60 3.12−57.8 94 5.62 3.14 −57.7 Mc Bath 62B 10 2.47 0.88 −59.9 17.5 5.80 2.06−61.0 20 7.32 2.60 −61.1 23 9.34 3.32 −60.8 26 10.30 3.66 −60.1 Mc Bath62A 10 2.95 1.05 −55.9 13.5 3.59 1.27 −56.8 17.5 5.40 1.92 −55.2 23 6.082.16 −57.2 26 6.26 2.22 −57.6 Mms 16a 66B 16 2.13 0.89 −65.5 18 2.591.09 −65.1 20.3 3.62 1.52 −65.5 27 5.50 2.31 −66.2 40.5 9.80 4.12 −66.3*DCW, Dry Cell Weight is reported in g/L calculated from the measuredoptical densities (OD₆₀₀) using specific correlation factors relating ODof 1.0 to 0.558 g/L for Mt OB3b, OD of 1.0 to 0.355 g/L for Mc Bath, andOD of 1.0 to 0.42 g/L for Mms 16a. For Mt OB3b, the initialconcentration of bicarbonate used per fermentation was 1.2 mM or 0.01%(Batch No. 68C) and 0.1% or 12 mM (Batch Nos. 68A and 68B). †EFT =effective fermentation time in hours

In addition, stable carbon isotope analysis was performed for biomassand corresponding lipid fractions (see Table 4) from strainsMethylosinus trichosporium OB3b (Mt OB3b), Methylococcus capsulatus Bath(Mc Bath), and Methylomonas sp. 16a (Mms 16a) grown on methane inbioreactors.

TABLE 4 Stable Carbon Isotope Distribution in Cells and Lipids Batch No.Strain δ¹³C Cells δ¹³C Lipids 68C Mt OB3b −57.7 −48.6 62A Mc Bath −57.6−52.8 66A Mms 16a −64.4 −42.2

Biomass from strains Mt OB3b, Mc Bath and Mms 16a were harvested at 94 h(3.14 g DCW/L), 26 h (2.2 g DCW/L) and 39 h (1.14 g DCW/L),respectively. The δ¹³C values for lipids in Table 4 represent an averageof duplicate determinations.

Example 4 Effect of Methane Source and Purity on Stable Carbon IsotopeDistribution in Lipids

To examine methanotroph growth on methane containing natural gascomponents, a series of 0.5-liter serum bottles containing 100 mLdefined media MMS1.0 were inoculated with Methylosinus trichosporiumOB3b or Methylococcus capsulatus Bath from a serum bottle batch culture(5% v/v) grown in the same media supplied with a 1:1 (v/v) mixture ofmethane and air. The composition of medium MMS1.0 was as follows: 0.8 mMMgSO₄*7H₂O, 30 mM NaNO₃, 0.14 mM CaCl₂, 1.2 mM NaHCO₃, 2.35 mM KH₂PO₄,3.4 mM K₂HPO₄, 20.7 μM Na₂MoO₄*2H₂O, 6 μM CuSO₄*5H₂O, 10 μMFe^(III)—Na-EDTA, and 1 mL per liter of a trace metals solution(containing, per L: 500 mg FeSO4*7H₂O, 400 mg ZnSO₄*7H₂O, 20 mgMnCl₂*7H2O, 50 mg CoCl₂*6H₂O, 10 mg NiCl₂*6H₂O, 15 mg H₃BO₃, 250 mgEDTA). Phosphate, bicarbonate, and Fe^(III)—Na-EDTA were added aftermedia was autoclaved and cooled. The final pH of the media was 7.0±0.1.

The inoculated bottles were sealed with rubber sleeve stoppers andinjected with 60 mL methane gas added via syringe through sterile 0.45μm filter and sterile 27G needles. Duplicate cultures were each injectedwith 60 mL volumes of (A) methane of 99% purity (grade 2.0, Praxairthrough Alliance Gas, San Carlos, Calif.), (B) methane of 70% purityrepresenting a natural gas standard (Sigma-Aldrich; also containing 9%ethane, 6% propane, 3% methylpropane, 3% butane, and other minorhydrocarbon components), (C) methane of 85% purity delivered as a 1:1mixture of methane sources A and B; and (D) >93% methane (grade 1.3,Specialty Chemical Products, South Houston, Tex.; in-house analysisshowed composition >99% methane). The cultures were incubated at 30° C.(M. trichosporium strain OB3b) or 42° C. (M. capsulatus Bath) withrotary shaking at 250 rpm and growth was measured at approximately 12hour intervals by withdrawing 1 mL samples to determine OD₆₀₀. At thesetimes, the bottles were vented and headspace replaced with 60 mL of therespective methane source (A, B, C, or D) and 60 mL of concentratedoxygen (at least 85% purity). At about 24 hour intervals, 5 mL sampleswere removed, cells recovered by centrifugation (8,000 rpm, 10 minutes),and then stored at −80° C. before analysis.

Analysis of carbon and nitrogen content (% dry weight), and carbon (¹³C)and nitrogen (¹⁵N) stable isotope ratios, for methanotrophic biomassderived from M. trichosporium strain OB3b and M. capsulatus Bath werecarried out as described in Example 3. Table 5 shows the results ofstable carbon isotope analysis for biomass samples from M. capsulatusBath grown on methane having different levels of purity and in variousbatches of bottle cultures.

TABLE 5 Stable Carbon Isotope Distribution of M. capsulatus Bath Grownon Different Methane Sources having Different Purity Methane* Batch No.Time (h)† OD₆₀₀ DCW (g/L) δ¹³C Cells A 62C 22 1.02 0.36 −40.3 56 2.010.71 −41.7 73 2.31 0.82 −42.5 62D 22 1.14 0.40 −39.3 56 2.07 0.73 −41.673 2.39 0.85 −42.0 B 62E 22 0.47 0.17 −44.7 56 0.49 0.17 −45.4 73 0.290.10 −45.4 62F 22 0.62 0.22 −42.3 56 0.63 0.22 −43.6 73 0.30 0.11 −43.7C 62G 22 0.70 0.25 −40.7 56 1.14 0.40 −44.8 73 1.36 0.48 −45.8 62H 220.62 0.22 −40.9 56 1.03 0.37 −44.7 73 1.23 0.44 −45.9 *Methane purity:A: 99% methane, grade 2.0 (min. 99%); B: 70% methane, natural gasstandard (contains 9% ethane, 6% propane, 3% methylpropane, 3% butane);C: 85% methane (1:1 mix of A and B methane) †Time = bottle culture timein hours

The average δ¹³C for M. capsulatus Bath grown on one source of methane(A, 99%) was −41.2±1.2, while the average δ¹³C forts. capsulatus Bathgrown on a different source of methane (B, 70%) was −44.2±1.2. Whenmethane sources A and B were mixed, an intermediate average δ¹³C of−43.8±2.4 was observed. These data show that the δ¹³C of cell materialgrown on methane sources A and B are significantly different from eachother due to the differences in the δ¹³C of the input methane. But,cells grown on a mixture of the two gasses preferentially utilize ¹²Cand, therefore, show a trend to more negative δ¹³C values.

A similar experiment was performed to examine whether two differentmethanotrophs, Methylococcus capsulatus Bath and Methylosinustrichosporium OB3b, grown on different methane sources and in variousbatches of bottle cultures showed a difference in δ¹³C distribution (seeTable 6).

TABLE 6 Stable Carbon Isotope Distribution of Different MethanotrophsGrown on Different Methane Sources of Different Purity Batch StrainMethane* No. Time (h)† OD₆₀₀ DCW (g/L) δ¹³C Cells Mc A 62I 18 0.494 0.18−54.3 Bath 40 2.33 0.83 −42.1 48 3.08 1.09 −37.1 Mc D 62J 18 0.592 0.21−38.3 Bath 40 1.93 0.69 −37.8 48 2.5 0.89 −37.8 Mc D 62K 18 0.564 0.20−38.6 Bath 40 1.53 0.54 −37.5 48 2.19 0.78 −37.6 Mt A 68D 118 0.422 0.24−50.2 OB3b 137 0.99 0.55 −47.7 162 1.43 0.80 −45.9 Mt A 68E 118 0.4740.26 −49.9 OB3b 137 1.065 0.59 −47.6 162 1.51 0.84 −45.2 Mt D 68F 1180.534 0.30 −45.6 OB3b 137 1.119 0.62 −38.7 162 1.63 0.91 −36.4 Mt D 68G118 0.544 0.30 −44.8 OB3b 137 1.131 0.63 −39.1 162 1.6 0.89 −34.2*Methane sources and purity: A: 99% methane (grade 2.0); D: >93% methane(grade 1.3) †Time = bottle culture time in hours

The average δ¹³C forts. capsulatus grown on a first methane source (A)was −44.5±8.8, while the average δ¹³C forts. trichosporium was −47.8±2.0grown on the same methane source. The average δ¹³C for M. capsulatusgrown on the second methane source (B) was −37.9±0.4, while the averageδ¹³C for M. trichosporium was −39.8±4.5. These data show that the δ¹³Cof cell material grown on a methane source is highly similar to the δ¹³Cof cell material from a different strain grown on the same source ofmethane. Thus, the observed δ¹³C of cell material appears to beprimarily dependent on the composition of the input gas rather than aproperty of a particular bacterial strain being studied.

The various embodiments described above can be combined to providefurther embodiments. All of the U.S. patents, U.S. patent applicationpublications, U.S. patent applications, foreign patents, foreign patentapplications and non-patent publications referred to in thisspecification and/or listed in the Application Data Sheet, includingU.S. provisional patent application Ser. No. 61/724,733, filed Nov. 9,2012, are incorporated herein by reference, in their entirety. Aspectsof the embodiments can be modified, if necessary to employ concepts ofthe various patents, applications and publications to provide yetfurther embodiments.

These and other changes can be made to the embodiments in light of theabove-detailed description. In general, in the following claims, theterms used should not be construed to limit the claims to the specificembodiments disclosed in the specification and the claims, but should beconstrued to include all possible embodiments along with the full scopeof equivalents to which such claims are entitled. Accordingly, theclaims are not limited by the disclosure.

1.-76. (canceled)
 77. A alpha-proteobacterial methanotroph, comprising aheterologous nucleic acid molecule encoding a fatty acid convertingenzyme, wherein the alpha-proteobacterial methanotroph comprising theheterologous nucleic acid molecule encoding the fatty acid convertingenzyme is capable of converting a C₁ substrate into a C₈-C₂₄ fattyaldehyde, fatty alcohol, fatty ester wax, a hydroxy fatty acid,dicarboxylic acid, or a combination thereof, and wherein the encodedfatty acid converting enzyme comprises: (a) a fatty acyl-CoA reductasecapable of forming a fatty alcohol; or (b) a fatty acyl-CoA reductasecapable of forming a fatty aldehyde; or (c) a carboxylic acid reductase;and (d) a thioesterase; and/or (e) an acyl-CoA synthetase.
 78. Thealpha-proteobacterial methanotroph according to claim 77, wherein thehost alpha-proteobacterial methanotroph is selected from Methylosinustrichosporium, Methylosinus sporium, Methylocystis parvus,Methylobacterium or ganophilum, Methylocella silvestris, Methylocellapalustris, Methylocella tundrae, Methylocella daltona, Methylocystisbryophila, Methylocapsa aurea, or high growth variants thereof.
 79. Thealpha-proteobacterial methanotroph according to claim 77, wherein the C₁substrate is methane, natural gas, or unconventional natural gas. 80.The alpha-proteobacterial methanotroph according to claim 77, wherein:(a) the fatty acyl-CoA reductase capable of forming a fatty alcohol isFAR, CER4, or Maqu_2220; or (b) the fatty acyl-CoA reductase capable offorming a fatty aldehyde is acr1.
 81. The alpha-proteobacterialmethanotroph according to claim 80, wherein: (a) the thioesterase is atesA lacking a signal peptide, UcFatB or BTE; and/or (b) the acyl-CoAsynthetase is a FadD, yng1, or FAA2.
 82. The alpha-proteobacterialmethanotroph according to claim 81, wherein: (a) endogenous thioesteraseactivity is reduced, minimal or abolished as compared to unalteredendogenous thioesterase activity; and/or (b) endogenous acyl-CoAsynthetase activity is reduced, minimal or abolished as compared tounaltered endogenous acyl-CoA synthetase activity.
 83. Thealpha-proteobacterial methanotroph according to claim 81, wherein thealpha-proteobacterial methanotroph further comprises a heterologousnucleic acid molecule encoding a P450 enzyme or monoxygenase enzyme toproduce ω-hydroxy fatty acid.
 84. The alpha-proteobacterial methanotrophaccording to claim 83, wherein endogenous alcohol dehydrogenase activityis inhibited as compared to unaltered endogenous alcohol dehydrogenaseactivity.
 85. The alpha-proteobacterial methanotroph according to claim81, wherein endogenous alcohol dehydrogenase activity is increased orelevated as compared to unaltered endogenous alcohol dehydrogenaseactivity to produce dicarboxylic acid.
 86. The alpha-proteobacterialmethanotroph according to claim 81, wherein the alpha-proteobacterialmethanotroph produces fatty alcohol comprising: (a) one or more ofC₈-C₁₄ or C₁₀-C₁₆ or C₁₄-C₂₄ fatty alcohols; (b) C₁₀ to C₁₈ fattyalcohol and the C₁₀ to C₁₈ fatty alcohols comprise at least 70% of thetotal fatty alcohol; or (c) a branched chain fatty alcohol.
 87. Thealpha-proteobacterial methanotroph according to claim 77, comprising:(a) a heterologous nucleic acid molecule encoding an acyl-CoAindependent fatty acyl-CoA reductase, and a heterologous nucleic acidmolecule encoding a thioesterase, wherein the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ fatty alcohol; (b) aheterologous nucleic acid molecule encoding an acyl-CoA dependent fattyacyl-CoA reductase, a heterologous nucleic acid molecule encoding athioesterase, and a heterologous nucleic acid molecule encoding anacyl-CoA synthetase, wherein the methanotroph is capable of converting aC₁ substrate into a C₈-C₂₄ fatty alcohol; (c) a heterologous nucleicacid molecule encoding a carboxylic acid reductase, a heterologousnucleic acid molecule encoding a phosphopantetheinyl tranferase, and aheterologous nucleic acid molecule encoding an alcohol dehydrogenase,wherein the methanotroph is capable of converting a C₁ substrate into aC₈-C₂₄ fatty alcohol; (d) a heterologous nucleic acid molecule encodinga fatty acyl-CoA reductase, a heterologous nucleic acid moleculeencoding a thioesterase, and a heterologous nucleic acid moleculeencoding a P450 or monooxygenase, wherein the native alcoholdehydrogenase is inhibited, and wherein the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ ω-hydroxy fatty acid; or (e) aheterologous nucleic acid molecule encoding a fatty acyl-CoA reductase,and a heterologous nucleic acid molecule encoding a thioesterase,wherein the methanotroph over-expresses native alcohol dehydrogenase ascompared to the normal expression level of native alcohol dehydrogenaseor comprises a heterologous nucleic acid molecule encoding an alcoholdehydrogenase or both, and wherein the methanotroph is capable ofconverting a C₁ substrate into a C₈-C₂₄ dicarboxylic acid alcohol. 88.The alpha-proteobacterial methanotroph according to claim 87, whereinthe alpha-proteobacterial methanotroph is selected from Methylosinustrichosporium OB3b, Methylosinus sporium, Methylocystis parvus, or ahigh growth variant thereof.
 89. A method for making a fatty acidderivative, comprising culturing a alpha-proteobacterial methanotrophwith a C₁ substrate feedstock and recovering the fatty acid derivative,wherein the alpha-proteobacterial methanotroph comprises a heterologousnucleic acid molecule encoding a fatty acid converting enzyme, whereinthe alpha-proteobacterial methanotroph converts the C₁ substrate into aC₈-C₂₄ fatty acid derivative comprising a fatty aldehyde, a fattyalcohol, fatty ester wax, a hydroxy fatty acid, a dicarboxylic acid, ora combination thereof, and wherein the encoded fatty acid convertingenzyme comprises: (a) a fatty acyl-CoA reductase capable of forming afatty alcohol; or (b) a fatty acyl-CoA reductase capable of forming afatty aldehyde; or (c) a carboxylic acid reductase; and (d) athioesterase; and/or (e) an acyl-CoA synthetase.
 90. The methodaccording to claim 89, wherein the alpha-proteobacterial methanotroph isselected from a Methylosinus trichosporium, Methylosinus sporium,Methylocystis parvus, Methylobacterium organophilum, Methylocellasilvestris, Methylocella palustris, Methylocella tundrae, Methylocelladaltona, Methylocystis bryophila, Methylocapsa aurea, or high growthvariants thereof.
 91. The method according to claim 89, wherein theculture further comprises a heterologous bacterium.
 92. The methodaccording to claim 89, wherein: (a) the fatty acyl-CoA reductase capableof forming a fatty alcohol is FAR, CER4, or Maqu_2220; or (b) the fattyacyl-CoA reductase capable of forming a fatty aldehyde is acr1.
 93. Themethod according to claim 89, wherein the thioesterase is a tesA lackinga signal peptide, UcFatB or BTE.
 94. The method according to claim 93,wherein endogenous thioesterase activity is reduced, minimal orabolished as compared to unaltered endogenous thioesterase activity. 95.The method according to claim 92, wherein the acyl-CoA synthetase isFadD, yng1, or FAA2.
 96. The method according to claim 92, whereinendogenous acyl-CoA synthetase activity is reduced, minimal or abolishedas compared to unaltered endogenous acyl-CoA synthetase activity. 97.The method according to claim 89, further comprising a heterologousnucleic acid molecule encoding a P450 enzyme or monoxygenase enzyme toproduce ω-hydroxy fatty acid.
 98. The method according to claim 97,wherein endogenous alcohol dehydrogenase activity is reduced, minimal orabolished as compared to unaltered endogenous alcohol dehydrogenaseactivity.
 99. The method according to claim 89, wherein endogenousalcohol dehydrogenase activity is increased or elevated as compared tounaltered endogenous alcohol dehydrogenase activity to producedicarboxylic acid.
 100. The method according to claim 89, wherein thealpha-proteobacterial methanotroph produces fatty alcohol comprising oneor more of C₈-C₁₄ or C₁₀-C₁₆ or C₁₂-C₁₄ or C₁₄-C₁₈ or C₁₄-C₂₄ fattyalcohols.
 101. The method according to claim 89, wherein thealpha-proteobacterial methanotroph produces fatty alcohol comprising C₁₀to C₁₈ fatty alcohol and the C₁₀ to C₁₈ fatty alcohols comprise at least70% of the total fatty alcohol.
 102. The method according to claim 89,wherein the alpha-proteobacterial methanotroph produces fatty alcoholscomprising a branched chain fatty alcohol.
 103. The method according toclaim 89, wherein the C₁ substrate is methane, natural gas, orunconventional natural gas.
 104. The method according to claim 89,wherein the C₁ substrate is methane, and the alpha-proteobacterialmethanotrophs are cultured under aerobic conditions.
 105. The methodaccording to claim 89, wherein the culturing is in a fermentor orbioreactor.
 106. An aerobic, facultative methanotrophic bacteria,comprising a heterologous nucleic acid molecule encoding a fatty acidconverting enzyme, wherein the facultative methanotrophic bacteriacomprising the heterologous nucleic acid molecule encoding the fattyacid converting enzyme is capable of converting a C₁ substrate underaerobic conditions into a C₈-C₂₄ fatty aldehyde, fatty alcohol, fattyester wax, a hydroxy fatty acid, dicarboxylic acid, or a combinationthereof, and wherein the encoded fatty acid converting enzyme comprises:(a) a fatty acyl-CoA reductase capable of forming a fatty alcohol; or(b) a fatty acyl-CoA reductase capable of forming a fatty aldehyde; or(c) a carboxylic acid reductase; and (d) a thioesterase; and/or (e) anacyl-CoA synthetase.
 107. The facultative methanotrophic bacteriaaccording to claim 106, wherein the host facultative methanotrophicbacteria is selected from Methylobacterium organophilum, Methylocellasilvestris, Methylocella palustris, Methylocella tundrae, Methylocelladaltona, Methylocystis bryophila, Methylocapsa aurea, or high growthvariants thereof.
 108. A methylotrophic bacteria, comprising aheterologous nucleic acid molecule encoding a fatty acid convertingenzyme, wherein the methylotrophic bacteria comprising the heterologousnucleic acid molecule encoding the fatty acid converting enzyme iscapable of converting a C₁ substrate under aerobic conditions into aC₈-C₂₄ fatty aldehyde, fatty alcohol, fatty ester wax, a hydroxy fattyacid, dicarboxylic acid, or a combination thereof, and wherein theencoded fatty acid converting enzyme comprises: (a) a fatty acyl-CoAreductase capable of forming a fatty alcohol; or (b) a fatty acyl-CoAreductase capable of forming a fatty aldehyde; or (c) a carboxylic acidreductase; and (d) a thioesterase; and/or (e) an acyl-CoA synthetase.109. The methylotrophic bacteria according to claim 108, wherein thehost methylotrophic bacteria is selected from Methylobacteriumextorquens, Methylobacterium radiotolerans, Methylobacterium populi,Methylobacterium chloromethanicum, Methylobacterium nodulans, or highgrowth variants thereof.